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Breast cancer is a heterogeneous disease that afflicts all patients differently, and 
therefore requires individualized treatment depending on a large variety of factors. 
Several methods of classification exist to divide patients into meaningful groups in order 
to better personalize their treatment regimens. Healthcare is evolving into more use of 
personalized treatments that can more effectively treat patients on an individual level, 
rather than by using more generalized treatments that may not prove effective in all 
patients. In addition, personalized treatment also aims to reduce adverse effects, while 
increasing effectiveness. 
Estrogen receptor (ER) status is one such method of grouping breast cancer 
patients into different treatment groups. Based on stage diagnosis and determination of 
receptor status, initial treatments such as surgery or radiotherapy may be used. 
Standard chemotherapy is another method, however, side effects may vary among 
patients and may be quite adverse. Other treatments include hormone or receptor 
blocking. This thesis has identified an alternatively spliced variant of classical ERα that 
resides in the plasma membrane of breast cancer cells and plays a major role in rapid 
signaling by estrogen. The overall aim of this thesis was to examine the role of the 
membrane receptor for 17β-estradiol (E2) in breast cancer that enhances breast tumor 
aggressiveness and to evaluate the mechanisms by which it functions. The general 
hypothesis was that nonclassical estrogen signaling through the proposed membrane-
associated ER, ERα36, can promote breast tumor aggressiveness by enhancing cell 
survivability while altering expression of angiogenic and metastatic factors. This work 
examined the mechanisms of ERα36-dependent signaling in breast cancer cells, and the 
correlation of ERα36 to clinical outcome in human breast cancer tissue through 
 xviii 
histological evaluation. These data provide significant research as they provide a greater 
understanding of estrogen signaling in breast cancer through ERα36 and its role in 
tumorigenicity and metastasis. This study also proposes further clinical examination of 
ERα36, and suggests drug design to target ERα36 followed by preclinical studies to 
determine if drugs targeting ERα36 would benefit breast cancer patients by reducing 
tumorigenicity and increasing survival. 
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1.1 Cancer: Causes, risks, and approaches to treatment 
Cancer comprises a large group of diseases that arise from abnormal cell 
growth. This cell growth can then lead to the formation of a neoplasm that may become 
malignant, leading to what is commonly known as a cancer. Cancerous tumors can arise 
in any tissue in the body, and local causes may vary from one tissue to another. Several 
factors have been identified as playing a role in cancer occurrence, but to identify a 
single cause of cancer is virtually impossible. Mutations occur normally during cell 
division, and several checkpoint proteins, one of the most recognizable being the tumor 
suppressor p53, are susceptible to mutations themselves. These proteins can regulate 
cell growth, but mutations in DNA can cause many of these proteins, either oncogenic or 
tumor suppressor proteins, to function abnormally, allowing further accumulation of 
mutations and eventually leading to unregulated cell proliferation.  
Mutations can occur spontaneously from the imperfect replication fidelity of DNA 
polymerase or may even be caused by external mutagens, either physical or 
chemical(1). Carcinogens, mutagens that cause cancer, have been identified from 
experimental evidence, and as individuals, we take it upon ourselves to limit exposure to 
carcinogens in everyday life. Unfortunately, although more than 90% of cancers arise 
specifically from external forces(2), several cancers are genetically inherited, and 
although all cancer patients should be treated with the ultimate goal of curing the 
disease, the unfortunate cases of genetic heredity of cancer pose more difficult 
approaches to prevention, diagnosis, and treatment. 
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As much as some would like to believe a cure for cancer is imminent, the 
majority of people making these statements are not scientists, and do not understand 
that cancer itself is not a single disease but rather a class of diseases. In addition, direct 
prevention of cancer is not as simple as that of many infectious diseases such as some 
virally-induced diseases that can be prevented and eradicated through effective 
vaccination(3). Because cancer is heterogeneous in development, and several causes 
exist, many of which are unknown, the most effective approach to alleviate the 
deleterious effects of cancer is by continually improving current treatments, and 
discovering novel approaches to personalized treatment and prevention. Early diagnosis 
of any cancer, but specifically breast cancer, is one of the most important ways to 
successfully combat the disease by allowing either complete removal of the neoplasias 
causing the disease, or by preventing further growth and eventual spread of the disease 
throughout the body. Cancer treatment is not performed with one specific approach. 
Rather, several approaches may be necessary for a single patient, beginning with 
surgery or radiotherapy and followed by adjunct chemotherapeutic approaches and 
lifestyle changes(2). Research into surgical techniques and radiotherapy are limited to 
the scope of the method, but possible additions to chemotherapeutic approaches are 
practically endless, due to the vast possibilities for drug targets, and the fact that new 
discoveries are constantly being made into identifying novel targets. Therefore, the 
identification of new targets for treatment is crucial to the development of effective and 
successful treatments that can specifically target and kill cancer cells, or prevent their 
growth. 
Breast cancer is one specific type of cancer in which environmental factors play a 
much smaller role in development of the disease than other factors. The primary risk 
factors for developing breast cancer are sex and age(4). Although less than 5% of breast 
 3 
cancer cases are attributed to genetic heredity(2), those citing such a statistic ignore the 
inherent fact that sex is specifically genetic and aging occurs in all individuals. Although 
this is a more philosophical argument for genetics being more responsible for breast 
cancer than other factors, it is undeniable that women are almost helpless in preventing 
breast cancer occurrence. 
As the most common non-cutaneous cancer among women in the United States, 
breast cancer is expected to afflict over 200,000 women in the United States in 2013, 
and according to the National Cancer Institute, almost 40,000 deaths are predicted to 
occur due to breast cancer in this year. Although the 5-year survival for breast cancer 
patients diagnosed in the early stages exceeds 90%, survival in patients with distant 
metastases drops below 25% indicating very poor prognosis for these patients(5). The 
complexities of breast cancer growth and metastasis present several problems in 
development of treatments for patients. Just as any form of cancer, breast cancer can 
present itself differently among patients. Although an actual cure for breast cancer is 
elusive, novel approaches to diagnosis and treatment can help to reduce mortality and 
allow patients, specifically those with more advanced stage cancer, to live normal lives. 
 
1.2 Estrogen biosynthesis 
 Estrogen is a general name for the group of hormones that are named for their 
role in the estrous cycles of females and are the primary female sex hormones, although 
they are still produced and function in males. The three naturally occurring steroidal 
estrogens are estrone (E1), estradiol (E2), and estriol (E3). Estradiol, the most commonly 
chemically substituted form being 17b-estradiol, is the most predominant estrogen in 
women during their reproductive years(6). After menopause, estrone is the predominant 
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estrogen, and during pregnancy, estriol is the predominant circulating estrogen. E2, 









As steroid hormones, estrogens arise from the conversion of cholesterol through 
several intermediary compounds. In the ovaries, estrogen is produced by conversion of 
the androgen, androstenedione, which serves as a precursor to other androgens such 
as testosterone and dihydrotestosterone, as well as the estrogenic compounds, estrone 
and estradiol. Several enzymes catalyze these conversions. 17b-hydroxysteroid 
dehydrogenase catalyzes the conversion of androstenedione to testosterone, while 
aromatase catalyzes the conversion of androstenedione or testosterone to estrone or 
estradiol, respectively. The biosynthesis of the androgens and estrogens with the 
enzymes that catalyze the key steps of the biosynthetic pathways is clearly illustrated in 
figure 2.1(8). Many of these enzymes can be produced by cells outside of the ovaries, 
especially aromatase(9), and this allows for conversion of androgens to estrogens 
locally, which is particularly important after menopause, when estrogen production from 
the ovaries dramatically declines(10, 11).  
 
1.3 Physiological roles of estrogen 
 As previously stated, estrogens are the group of primary female sex hormones 
that play major roles in body development and reproductive development. Estradiol is 
responsible for the formation of primary and secondary female sex characteristics, 
development of the uterus, and regulation of the menstrual cycle. In males, estrogen 
regulates male reproductive development, especially maturation of sperm. Numerous 
other developmental and structural changes are mediated by estrogen function, 
including regulation of skeletal development and breast development(12). These two 
functions are of particular interest as they are unfortunately affected by deficiency or 
abnormalities in estrogen signaling resulting in debilitating conditions, such as 
osteopenia or breast cancer progression(13, 14). Moreover, while estrogen normally 
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regulates osteoblast and osteoclast function, abnormal estrogen levels following 
menopause may result in dysregulation of bone remodeling, leading to decreases in 
bone mineral retention, and ultimately causing osteopenia, a precursor to 
osteoporosis(15). Causes of breast cancer are not as easily identified, but estrogen is 
well accepted as a mediator of breast cancer progression and abnormal estrogen can 
promote progression of hormone-responsive cancers, such as uterine, ovarian, cervical, 
and especially, breast cancer(16). Therefore, the functioning of estrogen and the role of 
estrogen receptors in normal and abnormal physiological conditions is extremely 
important to understand.  
 
1.4 Estrogen receptors and the classical nuclear receptor pathway 
Estrogens belong to the class of biomolecules known as the steroid hormones, 
which traditionally confer their effects through direct interaction with hormone-specific 
receptors. These include vitamin D3 metabolites such as 1α,25-dihydroxyvitamin-D3 
(1,25(OH)2D3) and 24R,25(OH)2D3 with the vitamin D3 receptor (VDR or nVDR), 
androgens such as testosterone and dihydrotestosterone with androgen receptors (AR), 
and most relevant to this study, estrogens, particularly estradiol, with the estrogen 
receptors, ERα and ERb(17). The classical mechanism by which steroid hormones such 
as 17b-estradiol elicit cellular effects begins with hormone binding to steroid hormone 
receptors in the cytosol, dimerization of receptors, either by homo- or heterodimerization, 
and translocation to the nucleus. In the nucleus, these hormone-receptor dimers 
traditionally function as transcription factors by binding to specific response elements on 
the DNA and either activating or repressing transcription(18). 
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1.5 Estrogen receptors and non-classical pathways 
Recently, there is increasing evidence of non-nuclear cytosolic or plasma 
membrane-associated receptors that mediate non-genomic effects of several steroid 
hormones(19-21). For some of these hormones, the traditional nuclear receptors have 
been found to function outside of the nucleus to direct non-genomic effects(22, 23), and 
in some cases, orphan receptors for many of these hormones have been identified that 
actually may be alternative receptors to the traditional steroid hormone receptors(21, 
24). Although some contention exists on the function of these non-traditional receptors, 
there is ample evidence to support the existence and ability of these receptors to bind 
their corresponding steroid hormones, one such example being the membrane receptor 
for 1,25(OH)2D3. Although several groups have identified nVDR in the plasma 
membrane(23, 25), protein disulfide isomerase family A, member 3 (PDIA3), traditionally 
recognized as a chaperone protein, has been the main focus as the potential membrane 
receptor for 1,25(OH)2D3. Also known as Erp60, Erp57, GRP58, and 1,25D3-MARRS, 
PDIA3 has been identified by numerous groups as a putative membrane receptor for 
1,25(OH)2D3(26-29). 
Classical steroid hormone signaling pathways that typically occur through 
hormone-dependent activation of receptors in the cytosol leading to transcriptional 
effects can take hours to days. However, steroid hormones can exert effects on cells 
rapidly within seconds to minutes through non-classical mechanisms outside of the 
nucleus. These can either be cytosolic or membrane-associated and their effects can be 
non-genomic, but crosstalk with genomic pathways can also occur(15, 19, 20, 30). The 
activation of signaling by steroid hormone receptor interaction with their corresponding 
hormones in the cytosol can activate signaling cascades that result in rapid activation of 
enzymes such as kinases or phospholipases that can lead to rapid physiological 
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changes in cells(19, 31). Typically these changes lead to activation of pathways that can 
affect cell proliferation or apoptosis. These pathways can also lead to downstream 
activation of transcription factors causing genomic regulation, which again takes hours to 
days. Figure 2.2 illustrates several mechanisms by which steroid hormones can activate 








These rapid signaling events cannot only occur in the cytosol, but can in fact be 
mediated through receptors residing in the plasma membrane. Lipid rafts are regions of 
the plasma membrane that are highly concentrated in cholesterol and proteins, 
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especially steroid hormone receptors. Caveolae are specialized lipid rafts that are 
characterized as membrane invaginations, which contain the specific caveolin proteins 
caveolin-1, caveolin-2, and caveolin-3(33). Several steroid hormone receptors have 
been found in caveolae, including the nVDR, PDIA3, and the traditional ERs(26, 28, 34-
41). It is possible that signaling through membrane-associated receptors can promote 
internalization of the receptors, but activation of these receptors at the membrane can in 
fact result in activation of signaling pathways directly without receptor translocation(41). 
The mechanism of how these receptors signal from the membranes is not completely 
understood, but in many cases, these responses are hypothesized to occur through 
what are known as membrane-delimited pathways(42, 43). In membrane-delimited 
signaling, G-proteins are activated and this activation leads to downstream activation of 
associated signaling cascades. If translocation of receptors occurs and the signaling 
does not in fact require membrane-associated proteins in order to mediate pathway 
activation, these responses might be considered membrane-associated or membrane-
mediated, rather than membrane-delimited, which actually require membrane activation 
of the receptors(44). Previous work in breast cancer cells showing the ability of E2 to 
rapidly activate PKC through membrane-associated signaling, actually shows that these 
effects are mediated through G-protein activation, suggesting that the membrane-
associated effect of E2 as far as PKC activation is concerned, is in fact through a 
membrane-delimited pathway. 
As far as estrogen signaling is concerned, the main candidates for membrane-
associated estrogen receptors include the traditional receptors ERα and ERb, but most 
recently, an orphan GPCR, GPR30 (also known as GPER), has been studied as a 
possible membrane-associated receptor for estrogen(45). However, the function and 
presence of GPR30 as a membrane-associated estrogen receptor, remains 
 10 
controversial, as some groups contend that it is strictly a cytosolic or endoplasmic 
reticulum-associated receptor(5, 46), while other groups have maintained that it is a 
membrane-associated receptor(47-49). While GPR30 remains a controversial candidate, 
several splice variants have been identified for the traditional receptors, both ERα and 
ERb. Until recently, two known splice variants of ERα had been identified: the traditional 
ERα, which has been alternatively named ERα66 to distinguish it from the other variants 
has a molecular weight of 66 kDa, and a lower molecular weight variant, ERα46, which 
not surprisingly has a molecular weight of 46kDa(39). Both ERα66 and ERα46 can 
translocate to the nucleus upon ligand binding, but they have also been identified in 
plasma membranes(39, 50-52). More recently, a novel ERα splice variant was 
discovered with a molecular mass of approximately 36 kDa and has been named ERα36 
(Figure 2.3). It differs from ERα66 by lacking both transcriptional activation domains 
(AF1 and AF2) (exons 7 and 8) but retains the DNA-binding domain and partial 
dimerization and ligand-binding domains(53). This suggests that although it may still 
bind to DNA, it may not directly activate transcription. It is possible that it may affect 
transcriptional function as a co-factor due to its ability to dimerize with other members 
and bind to DNA, but ERα36 also contains a novel exon 9, which encodes 27 amino 
acids of unknown function(53). There are limited data on the function of ERα36, but it 
has been found in the membranes of several cells and has been shown to mediate some 
rapid effects of estrogen(54-56). 
 11 
 
Figure 1.3: mRNA and protein domain maps of ERα splice variants 
 
 
Several studies have reported the presence of both ERα and ERβ in plasma 
membranes, including truncated forms of the receptors, suggesting that they may be 
involved in the membrane-mediated effects of E2. This is supported by studies using E2 
conjugated to bovine serum albumin (E2-BSA), which cannot pass through the plasma 
membrane and reach the nuclear receptor, yet it elicits many of the same effects as E2. 
E2 and E2-BSA rapidly increase protein kinase C (PKC)-specific activity without new 
gene expression or protein synthesis, and antibodies to nuclear and cytosolic ERα and 
ERβ as well as activators and inhibitors of classical ERs do not block this effect. 
However, which one of the ER isoforms is responsible is not known. 
 
1.6 Estrogen and Cancer 
 Estrogen receptor (ER) status is a major point of concern in diagnosis and 
treatment of breast cancer. Based on stage diagnosis and determination of receptor 
status, treatments such as surgery, chemotherapy, or radiotherapy may be used. Other 
treatments include hormone or receptor blocking. Growth of ER-positive breast cancers 
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is typically enhanced by estrogen, but ER interactions with DNA are not necessary for 
this growth to occur(57), suggesting that non-nuclear actions of ERs may play a role. 
ER-negative and triple negative breast cancers, which are ER-negative, progesterone 
receptor-negative, and human epidermal growth factor receptor 2-negative, are typically 
characterized as more aggressive and less responsive to hormone treatments(58). 
These tumors are also less responsive to treatments such as tamoxifen, a commonly 
used estrogen antagonist, which reduces tumor aggressiveness in ER-positive breast 
cancer and prevents recurrence of cancer after chemotherapy or radiotherapy. However, 
estrogen may have some effects in ER-negative breast cancers that are not fully 
understood, and with the discovery of novel splice variants of traditional ERs(53), 
patients with ER-negative breast cancer should not be assumed as nonresponsive to 
treatments typical for ER-positive breast cancer patients. Moreover, rapid responses to 
E2 and E2-BSA are seen in ERα-negative HCC38 breast cancer cells as well as in ERα-
positive MCF7 cells(57), suggesting that either ERβ is responsible or that another ERα 
isoform mediates the effects of E2. 
 ERα36 was shown to be involved in estrogen-stimulated MAPK (ERK) activation 
in HEK293 cells in which the receptor was overexpressed(55), as well as in 
testosterone-stimulated ERK and Akt activation in endometrial cancer cells(59), raising 
the possibility that this ERα isoform is involved. The G-protein-coupled receptor GPR30 
has also been shown to mediate non-nuclear responses of estrogen and has been 
reported as an alternative membrane receptor for E2(60). However, Kang et al reported 
that GPR30 is not responsible for nongenomic signaling of estrogen in the context of 
rapid enzyme activation such as ERK1 and ERK2(61). While GPR30 has been 
hypothesized as a receptor for estrogen, ERα36 is known to retain a ligand-binding 
domain for estrogen; however, it does not retain transcriptional activation function, 
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suggesting that it may have functions unrelated to traditional nuclear receptor 
transcriptional function in breast cancer cells, particularly ERα-negative breast cancer 
cell that respond to estrogen. 
Epidemiological studies have implied that sex hormones are involved in the 
tumorigenesis of not only breast cancer but also several other cancers, especially 
cancers that are thought of as sex-specific cancers(62-64). The larynx is a secondary 
sex organ, which undergoes trophic changes in response to hormonal changes during 
puberty, and morphostructural changes during adulthood. Nonetheless, while other 
tumors of secondary sex organs have been accepted as hormone dependent 
cancers(65-67), laryngeal carcinoma is still a subject of controversy, and as such, its 
treatment is not oriented to counteract the hormonal effect.  
 
1.7 Thesis objective 
This thesis aims to gain a better understanding of the role of E2 in breast cancer 
tumorigenicity and progression. The research presented used in vitro approaches to 
identify the receptor responsible for the membrane-mediated effects of E2 in breast 
cancer cells, and to elucidate the mechanism by which it functions. Similar effects were 
examined in other cancers to determine if these effects and the role of the membrane 
receptor are present in a more generalized context of cancer. Finally, human cancer 
tissues were examined histologically to determine if the membrane receptor may provide 
diagnostic value in vivo or if it could potentially be a suitable target for drug design for 
novel treatments. 
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The complexities of breast cancer growth and metastasis present several 
problems in development of treatments for patients. Just as any form of cancer, breast 
cancer can present itself differently among patients. Estrogen receptor (ER) status is a 
major point of concern in diagnosis and treatment. Based on stage diagnosis and 
determination of receptor status, treatments such as surgery, chemotherapy, or 
radiotherapy may be used. Other treatments include hormone or receptor blocking. We 
have previously shown that E2 can induce rapid, non-genomic activation of PKC in 
breast cancer cells leading to enhanced proliferation in vitro. At the time, we did not 
identify a receptor that mediates this effect, but we did determine that the effect was 
membrane-mediated. Recently, a novel alternatively spliced variant of classical ERα 
known as ERα36 has been cloned and identified in breast cancer cells. This study 
provides a better insight into mechanisms by which estrogen enhances breast cancer 
tumorigenicity and metastasis. The overall objective was to identify the membrane 
receptor for 17β-estradiol (E2) in breast cancer that enhances breast tumor 
aggressiveness and to evaluate the mechanisms by which it functions. The general 
hypothesis was that nonclassical estrogen signaling through the membrane-associated 
ER, ERα36, can promote breast tumor aggressiveness by enhancing cell survivability 
while altering expression of angiogenic and metastatic factors. The alternative to this 
hypothesis was that rapid effects of estrogen on breast cancer cells occur through other 
mechanisms including ERβ or other nonclassical ERs, such as GPR30. The overall 
approach used antibody blocking, protein inhibition, gene silencing, and mutagenesis to 
assess the role of ERα36 in rapid membrane signaling leading to tumorigenicity and 
metastasis of breast cancer cells. Three specific aims were to be evaluated in order to 
address the hypothesis: 
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2.1  Specific Aim 1: To determine if the estrogen receptor, ERα36, plays a role in 
rapid membrane signaling of E2 in breast cancer cells and if this signaling leads to 
enhanced breast cancer cell survivability in vitro 
 
Rapid protein kinase C (PKC) activation occurs in response to estrogen 
treatment in both ERα-positive MCF7 and ERα-negative HCC38 breast cancer cells. 
PKC is associated with enhanced tumorigenicity(1). The objective was to examine the 
mechanism by which E2 can cause rapid signaling events in breast cancer cells that do 
not contain classical forms of ERα and to determine the physiological effects of these 
signaling events. The hypothesis was that E2-induced rapid PKC activation in breast 
cancer cells is mediated by ERα36 from the membrane. The alternative hypothesis is 
that ERβ, the non-classical ER, GPR30, or another unidentified receptor of estrogen that 
resides on the membrane mediates the rapid activation of PKC in breast cancer cells. 
ER blocking by specific antibodies and RNA interference was used to determine 
the specific receptor responsible for the membrane response of E2. The antibodies and 
RNA interference targeted known splice variants of ERα, ERβ, and the nonclassical ER, 
GPR30. The mechanism of action of E2 through this receptor was elucidated further by 
analysis of localization and determination of associated signaling events followed by 
examination of the pro-proliferative and anti-apoptotic effects of E2. Following initial 
studies, the effects of E2 on enhanced cell survivability were examined by analysis of 
DNA synthesis, cell viability, and apoptosis. In order to examine E2’s antiapoptotic 
effects in these breast cancer cells, taxol, a common chemotherapeutic agent used in 
breast cancer treatment, will be used to induce apoptosis followed by treatment with E2 
to determine if E2 can promote anti-apoptosis. 
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2.2 Specific Aim 2: To determine the mechanism by which ERα36 mediates the 
membrane-associated effect of E2 in breast cancer cells and if this pathway exists 
on other cancers 
 
ERα has three known alternatively-spliced variants: the traditional ERα66, as well 
as the more recently identified ERα46 and ERα36(53). Interestingly, our preliminary 
results showed that HCC38 breast cancer cells do not express ERα66 and ERα46, but 
do express ERα36. The mRNA for ERα66 is coded for by 8 exons containing 
characteristic features of traditional steroid hormone receptors such as transcriptional 
activation domains (AF1 and AF2), a DNA-binding domain (DNABD), a ligand-binding 
domain (LBD), and regions that confer dimerization. ERα36 retains the DNABD, LBD, 
and partial dimerization, but does not retain AF1 or AF2. Intriguingly, ERα36 also 
contains a novel exon (exon 9) not found in the mRNA of ERα66 that codes for 27 amino 
acids of unknown function. 
Previous work has shown that E2 can rapidly activate PKC in MCF7 and HCC38 
cells via phosphatidyl inositol specific phospholipase C (PI-PLC) and G-protein(57). Non-
genomic signaling of the vitamin D3 metabolite, 24R,25-dihydoxyvitamin-D3 has been 
shown to mediate anti-apoptosis through activation of PLD, LPA, and PI3K in 
chondrocytes(68), while estrogen is known to be anti-apoptotic in ER-positive breast 
cancer cells(69).  The objectives were to elucidate the mechanistic pathway of E2’s 
effects on breast cancer cells via membrane signaling and to determine if exon 9 of 
ERα36 is required in mediating the membrane-initiated effect of E2 in breast cancer. The 
hypotheses were as follows: (1) E2 interaction with ERα36 in breast cancer cells leads 
to activation of a pathway involving G-protein, PI-PLC, and PLD, and this pathway 
results in activation of PKC, leading to anti-apoptotic effects of E2 in breast cancer cells, 
and (2) exon 9 is necessary for mediating rapid signaling of E2 from the plasma 
 17 
membrane. The alternative hypotheses were that E2 functioning through ERα36 
activates a separate pathway from that including PLC and PLD activation such as 
activation of phospholipase A2 (PLA2), and exon 9 plays no role in the membrane-
mediated functioning of ERα36 in breast cancer cells. Complete deletion of exon 9 was 
performed in order to evaluate its function. To examine the PKC activation pathway in 
HCC38 cells, functional analyses using antibodies and inhibitors to specific mediators in 
the hypothesized pathway were performed to determine involvement. In addition, we 
wanted to determine if ERα36 can mediate similar effects in other cancers, or if these 
effects are limited only to breast cancer. Therefore, we also performed similar studies in 
thyroid and laryngeal cancer cells. 
 
2.3 Specific Aim 3: To examine the role of ERα36 in enhancing breast cancer 
aggressiveness and metastasis, and to determine its role in vivo 
 
Several factors associated with tumor metastasis are known to be up-regulated 
in breast carcinomas. The molecular mechanisms of breast cancer metastases, which 
commonly occur in bone, are not well understood. The general events that lead to 
metastatic cancer include initial tumor formation, growth and vascularization, 
detachment and migration, and eventual re-localization of tumorigenic cells to secondary 
sites of the body such as bone. The objectives were to examine presence of ERα36 in 
human breast cancer tissue and determine if ERα36 presence can predict clinical 
outcome. The hypothesis was that ERα36 presence is associated with VEGF presence 
and clinical variables that are related to poor clinical outcome. 
In evaluating aim 1, we examined the indirect genomic effect of this membrane-
mediated signaling of E2 through ERα36 on the production of angiogenic growth factors, 
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migratory factors, and osteoclastogenic factors, thereby allowing us to further 
understand the mechanism by which breast cancer progresses in vitro. Following up with 
this study, we determined if there is a correlation between expression and presence of 
ERα36 and clinicopathological variables of the cancer in vivo in blinded analysis of 
tissue samples from breast tumors of patients diagnosed with varying stages of breast 
cancer. 
The outcomes of this work were expected to show that signaling via ERα36 could 
enhance cell proliferation, protection against apoptosis, and production of growth factors, 
and other proteins that promote tumor aggressiveness and metastasis. This research is 
significant because it provides a greater understanding of estrogen signaling in breast 
cancer and its role in tumorigenicity and metastasis. The study provides scientific 
support for the targeting of ERα36 for drug design or gene therapy in the diagnosis and 
treatment of metastatic breast cancer. 
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CHAPTER 3: Membrane Estrogen Signaling Enhances Tumorigenesis and 




[Chapter 3 is published as: Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, 
Boyan BD, Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and 
metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J 




Protein kinase C (PKC) signaling can be activated rapidly by 17β-estradiol (E2) 
via nontraditional signaling in ERα-positive MCF7 and ERα-negative HCC38 breast 
cancer cells and is associated with tumorigenicity. Additionally, E2 has been shown to 
elicit anti-apoptotic effects in cancer cells counteracting pro-apoptotic effects of 
chemotherapeutics. Supporting evidence suggests the existence of a membrane-
associated ER that differs from the traditional receptors, ERα and ERβ. Our aim was to 
identify the ER responsible for rapid PKC activation and to evaluate downstream effects, 
such as proliferation, apoptosis, and metastasis. RT-PCR, Western blot, and 
immunofluorescence were used to determine the presence of ER splice variants in 
multiple cell lines. E2 effects on PKC activity were measured with and without ER-
blocking antibodies. Cell proliferation was determined by [3H]-thymidine incorporation, 
and cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, (MTT) whereas apoptosis was determined by DNA fragmentation and TUNEL. 
Quantitative RT-PCR and sandwich ELISA were used to determine the effects on 
metastatic factors. The role of membrane-dependent signaling in cancer cell 
invasiveness was examined using an in vitro assay. The results indicate the presence of 
an ERα splice variant, ERα36, in ERα-positive MCF7 and ERα-negative HCC38 breast 
cancer cells, which localized to plasma membranes and rapidly activated PKC in 
response to E2, leading to deleterious effects such as enhancement of proliferation, 
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protection against apoptosis, and enhancement of metastatic factors. These findings 
propose ERα36 as a novel target for the development of therapies that can prevent 
progression of breast cancer in the primary tumor as well as during metastasis. 
 
3.1 INTRODUCTION 
The complexities of breast cancer growth and metastasis present several 
problems in development of treatments for patients. The main screening process in 
determining the treatment and prognosis of breast cancer patients is receptor status. 
Growth of estrogen receptor (ER)-positive breast cancers is typically enhanced by 
estrogen, but ER interactions with DNA are not necessary for this growth to occur (70, 
71), suggesting that non-nuclear actions of ERs may play a role. Triple negative breast 
cancers, which are ER-negative, progesterone receptor (PR) negative, and human 
epidermal growth factor receptor 2 (HER2) negative, are typically characterized as more 
aggressive and less responsive to hormone treatments (72). These tumors are also less 
responsive to treatments such as tamoxifen, a commonly used estrogen antagonist, 
which reduces tumor aggressiveness in ER-positive breast cancer and prevents 
recurrence of cancer after chemotherapy or radiotherapy (73). However, estrogen may 
have some effects in ER-negative breast cancers that are not fully understood, and with 
the discovery of novel splice variants of traditional ERs (74, 75), patients with ER-
negative breast cancer should not be assumed as non-responsive to treatments typical 
for ER-positive breast cancer patients. 
Steroid hormone receptors traditionally function as transcription factors upon 
ligand binding, but many studies have identified them in plasma membranes and have 
shown that they can rapidly activate signal transduction pathways, leading to events 
such as increased proliferation or attenuated apoptosis (21). Estrogens, in particular, 
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elicit many of their effects on cells through classical steroid hormone receptor 
mechanisms involving two primary receptor classes: ERα and ERβ. 
It is now understood that 17β-estradiol (E2) exerts some of its effects via 
signaling mechanisms other than traditional nuclear receptor-mediated pathways (70, 
76-78). Several studies have reported the presence of both ERα and ERβ in plasma 
membranes (21, 70), including truncated forms of the receptors, suggesting that they 
may be involved in membrane-mediated effects of the hormone. This is supported by 
studies using E2 conjugated to bovine serum albumin (E2-BSA), which cannot pass 
through the plasma membrane and reach the nuclear receptor, yet elicits many of the 
same effects as E2 (57, 79, 80). E2 and E2-BSA rapidly increase protein kinase C (PKC) 
specific activity without new gene expression or protein synthesis, and antibodies to 
nuclear and cytosolic ERα and ERβ, as well as activators and inhibitors of classical ERs 
do not block this effect (57). However, which one of the ER isoforms is responsible is not 
known. Moreover, rapid responses to E2 and E2-BSA are seen in ERα-negative HCC38 
breast cancer cells as well as in ERα-positive MCF7 cells (57), suggesting that either 
ERb is responsible or that another ERα isoform mediates E2’s effects.   
There are multiple isoforms of ERα: the traditional ERα66 (MW=66 kDa) and a 
lower molecular weight variant ERα46. Both ERα66 and ERα46 are localized to the 
nucleus upon ligand binding (53). Recently, a novel ERα variant was discovered with a 
molecular mass of approximately 36 kDa (ERα36) (53, 55, 59). It differs from ERα66 by 
lacking both transcriptional activation domains (AF1 and AF2) (exons 7 and 8), but 
retains the DNA-binding domain and partial dimerization and ligand-binding domains 
(53). It also contains a novel exon 9, which encodes 27 amino acids of unknown 
function. ERα36 was shown to be involved in estrogen-stimulated mitogen activated 
protein kinase (ERK) activation in HEK293 cells in which the receptor was 
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overexpressed as well as in testosterone-stimulated ERK and Akt activation in 
endometrial cancer cells (55), raising the possibility that this ERα isoform is involved.  
The G-protein coupled receptor GPR30 has also been shown to mediate non-
nuclear responses of estrogen and has been reported as an alternative membrane 
receptor for E2 (81). Kang et al reported that GPR30 is not responsible for non-genomic 
signaling of estrogen in the context of rapid enzyme activation such as ERK1 and ERK2 
(82). However, we show in this study that GPR30 does not play a role in membrane-
associated E2-dependent cell proliferation, but it is not known if GPR30 mediates other 
responses related to apoptosis or metastasis and further examination is needed. 
The purpose of the present study was to evaluate the role of ERα36 in 
membrane-associated estrogen signaling in breast cancer. We hypothesized that 
ERα36-associated E2 membrane signaling in breast cancer cells leads to enhanced 
cancer cell survival by promoting proliferation, protecting against apoptosis, and 
stimulating downstream gene expression associated with enhanced tumorigenicity and 
metastasis. The main goal of this investigation was to help us gain a greater 
understanding of the underlying mechanisms of breast cancer tumor aggression and 
invasion, providing us with new knowledge vital in the development of novel treatments 
to control breast cancer growth and metastasis. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Reagents 
ERα-positive MCF7 and ERα-negative HCC38 human breast cancer cells as well 
as SkBr3, COS7, and HeLa cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). The PKC assay kit was purchased from GE 
 23 
LifeSciences (Piscataway, NJ). Minimal essential media (MEM) and Roswell Park 
Memorial Institute 1640 media (RPMI 1640) were purchased from Gibco/Invitrogen 
(Carlsbad, CA). Charcoal-dextran filtered fetal bovine serum (CD-FBS) was purchased 
from Hyclone (Logan, UT). E2, E2-BSA, and taxol (paclitaxel) were purchased from 
Sigma-Aldrich (St. Louis, MO). Chelerythrine, a PKC inhibitor, was purchased from EMD 
Chemicals (Gibbstown, NJ). Protein content of samples was measured using the Macro 
BCA reagent kit from Pierce Chemicals/Thermo Scientific (Rockford, IL). Primers were 
purchased from Eurofins (Des Moines, IA). Reverse transcription and polymerase chain 
reaction (PCR) reagents were purchased from BioRad, Inc. (Hercules, CA). Quantitative 
reverse transcription PCR (qRT-PCR) reagents were purchased from Applied 
Biosystems (Carlsbad, CA). [32P]-ATP and [3H]-thymidine were obtained from Perkin-
Elmer (Boston, MA). Polyclonal ERα66 and ERα36 antibodies were purchased from Chi 
Scientific (Maynard, MA). Polyclonal ERβ and monoclonal glyceraldehyde-3-phosphate 
de-hydrogenase (GAPDH) antibodies were obtained from Millipore (Billerica, MA). 
Polyclonal antibodies to caveolin-1 and GPR30 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Monoclonal antibodies to cytochrome C oxidase (COX) 
IV were from Abcam (Cambridge, MA). Goat anti-rabbit-horse radish peroxidase (HRP) 
and goat anti-mouse-HRP conjugated secondary antibodies were obtained from BioRad. 
Goat anti-rabbit Alexa 488, goat anti-rabbit Alexa 594, Hoechst 4322 (nuclear stain), and 
Select FX 488 endoplasmic reticulum stain were purchased from Molecular Probes 
(Carlsbad, CA). 
 
3.2.2 Cell Culture 
All cells (SkBr3, MDA-MB-231, HEK293, and COS7) were cultured in appropriate 
media as specified by the ATCC containing 10% charcoal/dextran-filtered FBS and 
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lacking phenol red, which can mimic the effects of E2 at low levels. MCF7 cells were 
maintained in minimum Eagle's-based media, and HCC38 cells were maintained in 
RPMI 1640-based media. 
 
3.2.3 Presence of ER Isoforms 
In order to determine if ERα36 is expressed in both ERα-positive MCF7 and 
ERα-negative HCC38 breast cancer cells, we designed sequence-specific primers that 
would selectively identify the three known alternative splicing variants of ERα: ERα66, 
ERα46, and ERα36. Primers used are shown in Table 3.1. Due to the sequence 
homology of ERα66 and ERα46, we could not identify ERα46 mRNA independent of 
ERα66. However, due to the existence of exon 9, which is not expressed in ERα66 or 
ERα46 (53), we successfully designed primers that spanned this exon in order to 
analyze expression of ERα36. 
 
 
Table 3.1: Primer sequence for ERα splice variants. 
Vector NTI software was used to determine alignment of the three alternatively spliced 
variants for ERα: ERα66, ERα46, and ERα36. We determined that it is not possible to 
distinguish ERα46 from ERα66, however it is possible to recognize ERα66 from both 
smaller isoforms. Primers were designed for ERα66 that spanned exon 1 in its mRNA. 
Primers for ERα46 and ERα66, designated for ERα46/66, spanned exons 7 and 8, which 
are both found in ERα46 and ERα66. Finally, primers for ERα36 were designed to span 
exon 9. 
Target Primer direction Sequence (5’ to 3’) 
ERα66 Sense TGCCTGGAGTGATGTTTAAGC 
 Antisense ACGGGAGCAAGTGCAGTC 
ERα66/46 Sense CCACACGGTTCAGATAATCC 
 Antisense ATCCCTTTGGCTGTTCCC 
ERα36 Sense GTGGTTTCCTCGTGTCTAAAGC 
 Antisense GGTGTTGAGTGTTGGTTGCC 
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RNA was extracted from cells using the TRIzol method. Reverse transcription 
was performed to produce cDNA for various ERs from both MCF7 and HCC38 cells as 
well as several other cell lines reported as lacking ERα including SkBr3, MDA-MB-231, 
HEK293 and COS7 (83-85). PCR was then performed in order to determine if mRNAs 
for the various alternative splice variants of ERα were expressed in these cells.   
Western blots of isolated membrane fractions were used to determine the 
subcellular location of ERα36. For western blots of whole cell lysates, cells were lysed 
with RIPA buffer containing 5mM NP-40 (Sigma-Aldrich). We first performed western 
blots using unfiltered lysates from MCF7, HCC38, and COS7 cells, which are derived 
from a non-human primate embryonic kidney cell line, and reported to not contain ERs 
(85). Whole cell lysates were filtered with a molecular weight cut-off of 100kDa prior to 
separation on 4-20% SDS-polyacrylamide gels (SDS-PAGE). In addition, cell lysates 
were fractionated according to the method previously described by Smart et al. (86) in 
order to obtain crude nuclear, plasma membrane, and pure caveolae fractions. 
Following SDS-PAGE of the isolated membrane fractions, protein was 
transferred onto nitrocellulose. Membranes were blocked with 2% bovine serum albumin 
in 1X phosphate buffered saline (PBS) containing 0.05% Tween-20 (Sigma-Aldrich) and 
probed with primary antibodies. Secondary HRP-conjugated antibodies were used for 
detection by chemiluminescence using the West Pico Chemiluminescence Substrate kit 
(Pierce Biotechnologies, Rockford, IL).  
Immunofluorescence microscopy was used to identify the subcellular localization 
of ERa66 and ERα36 in MCF7 cells. Cells were cultured on 4-well chamber slides. At 
the time of harvest, cells were fixed with 4% paraformaldehyde. Some samples were 
then permeabilized with 0.01% Triton-X 100 for 10 minutes and subsequently stained for 
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ERs using specific antibodies. These samples were imaged with a Leica DMLB 
fluorescent microscope using a Hamamatsu Orca camera. To determine if ERα36 
colocalizes to lipid rafts and caveolae, cells fixed in chamber slides were either pre-
stained for lipid rafts (Vybrant Lipid Raft Labeling kit, Invitrogen, Carlsbad, CA) and/or 
probed with antibodies against ERα36 and protein disulfide isomerase (PDI) 
(endoplasmic reticulum) followed by incubation with fluorescent-tagged secondary 
antibodies (488 and 594nm). All samples were treated with Hoechst dye for nuclear 
staining (333nm). These samples were then imaged using a Nikon LSM510 confocal 
laser-scanning microscope and multiple Z-slices were obtained in order to obtain 
representative images. 
 
3.2.4 PKC Activity 
To determine if ERa36 mediated the stimulatory effect of E2 on PKC activity, 
MCF7 and HCC38 cells were cultured to confluence in 24-well tissue culture-treated 
plates. Cells were pre-treated with antibodies against ERα36 followed by treatment with 
E2 for 9 minutes. Cells were washed two times in cold 1XPBS and lysed using RIPA 
buffer at time of harvest. Samples were then aliquoted and assayed for protein content 
by Macro BCA protein assay (Pierce Biotechnologies) and measurement of PKC 
activation using the Biotrak Protein Kinase C Assay kit (GE LifeSciences).  
HCC38 cultures were also treated with 1mM methyl β-cyclodextrin (MebCD) for 
30 minutes to deplete the membranes of cholesterol, thereby disrupting the caveolae 
and lipid rafts (34). The cells were then treated with E2 for 9 minutes and protein content 
and PKC activity were determined as described.  
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3.2.5 Cell Proliferation, Viability, and Apoptosis 
In order to determine the consequences of rapid activation of PKC in the context 
of breast cancer cell survival we performed assays to determine the effect of inhibiting 
PKC on apoptosis and proliferation. PKC activity was inhibited using chelerythrine as 
described previously (57). Confluent cultures of HCC38 cells were cultured in the 
presence of 0.1µM, 1.0µM, and 10µM chelerythrine for 24 hours and MTT was 
measured. In addition, HCC38 cells were treated with 5mM and 7.5mM phosphate to 
induce apoptosis, as we have previously shown that phosphate induces apoptosis in 
other cell types (87). We previously showed that tamoxifen, an ER agonist that inhibits 
PKC, blocks the stimulatory effects of E2 on proliferation. Finally to determine if ERα36 
mediates the anti-apoptotic effect of E2, we took advantage of the observation that E2 
inhibits taxol-induced apoptosis via membrane-associated signaling (69). Sub-confluent 
cultures of HCC38 cells were pretreated with E2 for 90 minutes followed by taxol 
treatment for 4 hours after which cells were assays for caspase-3 activity and TUNEL. 
Cell proliferation was assessed as a function of [3H]-thymidine incorporation, as 
described previously (57). Subconfluent cultures of HCC38 cells were made quiescent 
by starvation for 48 hours prior to treatment in starvation media containing 0.1% 
charcoal-dextran filtered FBS. Cells were then treated with varying concentrations of E2 
or E2-BSA for 24 hours. In addition, cells were treated with antibodies to ERa36 and 
GPR30. At 20 hours after the start of treatment time, 1.0mCi/mL of [3H]-thymidine was 
added to all samples for the remainder of the treatment. At 24 hours, media were 
removed and cells were washed two times with 1X PBS. Cells were then fixed by 
washing three times with cold 5% trichloroacetic acid (TCA). During the third wash, the 
TCA was left on the cells for 30 minutes at 4°C. After fixation, the TCA was removed and 
the cell layers were allowed to dry at which point, 100mL of 1% sodium dodecyl sulfate 
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was added. The cell layers were then scraped and transferred to glass scintillation vials 
for measurement of radioactive decay (DPM) to determine relative incorporation of [3H]-
thymidine.   
The number of viable cells was determined by the MTT assay, which measures 
the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide (Sigma-
Aldrich) to purple formazan by mitochondrial reductase of living cells. In order to 
determine the role of PKC signaling in breast cancer cell viability, confluent cultures of 
HCC38 cells were treated with the PKC inhibitor chelerythrine (10-7, 10-6, and 10-5 M) 
for 24 hours and MTT activity and DNA fragmentation were measured. In order to 
determine if signaling via ERα36 could protect breast cancer cells against apoptosis, 
HCC38 cells were treated with E2 and E2-BSA in conjunction with taxol, which induces 
cell death in breast cancer cells (88). Apoptosis was assessed using DNA fragmentation 
as described previously (89). TUNEL assay was used to determine the protective effect 
of E2 against taxol-induced cell death. In addition, caspase-3 activity was measured 
using the CaspAce assay kit from Promega (Madison, WI).  
 
3.2.6 E2 Effects on Factors that Promote Bone Metastasis 
Breast cancer has a particular affinity for metastasizing to bone (90, 91). 
Therefore, we measured the effects of E2 and E2-BSA on expression of factors 
associated with bone metastasis at 12 hours. qRT-PCR was used to determine the 
quantitative effect of E2 on expression of receptor activator of nuclear factor kappa-B 
ligand (RANKL), Snail1, and e-cadherin (CDH1) in HCC38 cells. In addition, we 
assessed expression of C-X-C chemokine receptor type 4 (CXCR4), which is a receptor 
for the chemotactic ligand, stromal cell-derived factor-1 (SDF1) that is present in high 
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levels in bone (92), syndecan-4, which is involved cell interaction with matrix (93), and 
matrix metalloproteinase-9 (MMP9), which has been shown to be regulated through 
signaling of ERα (93). We also examined the effects of E2-BSA on secretion of factors 
related to osteoclast activation and inhibition. Sandwich ELISAs, were used to measure 
levels of osteoprotegerin (OPG) and interleukin-6 (IL6) (R&D Systems, Minneapolis, MN) 
in the conditioned media 24 hours after treatment with E2 or E2-BSA.  
 
3.2.7 Scratch-wound assay to measure in vitro breast cancer cell invasion 
A 10µL micropipette tip was used to create scratch-wounds in confluent cultures 
of HCC38 cells. After washing with media to remove detached cells and debris, the 
cultures were treated with E2-BSA, anti-ERα36 antibody, or both. Phase-contrast images 
were obtained at the beginning of the assay as well as at 6 and 12-hour increments until 
all wounds were healed. MatLab was used to quantify mean diameter of the wounds 
over time and data are presented as percent wound closure. 
 
3.2.8 Statistical Analyses 
For all experiments, statistical analyses were performed by analysis of variance 
(ANOVA) with Bonferroni’s correction for multiple comparisons at a significance level of 






3.3.1 ERα36 Is Expressed in Both ERα-positive and ERα-negative Cells 
Fig. 3.1A shows the different exons expressed in the mRNA of the three known 
splice variants of ERα. RT-PCR analysis showed expression of all ERα variants in MCF7 
cells. HCC38 cells expressed only ERα36; neither ERα46 nor ERα66 was detected by 
RT-PCR. We performed a screen of more than 20 human cell lines for the expression of 
ERα36 and did not find a suitable negative control for ERα36 expression (data not 
shown). MDA-MB-231, SkBr3, and HEK293 cells exhibited expression of only ERα36 but 
not the other variants of ERα (Figure 3.1, A and B). COS7 African green monkey 
embryonic kidney cells, although they do not express ERα36, are not a relevant negative 
control for our studies as they are not human cells, and they are of embryonic origin. All 





Figure 3.1: mRNA expression and protein presence of ERα splice variants in MCF7 
and HCC38 cells. 
(A) Different cell types show variable expression of ERα splicing variants. MCF7 express 
all variants, while ERα-negative HCC38, MDA-MB-231, SkBr3, and HEK293 cells only 
express ERα36. (B) Western blots of unfiltered cell lysates verify protein presence of 
ERβ and ERα36 in MCF7 and HCC38 cells but no ERα36 in COS7 cells. Filtered lysates 
of MCF7 and HCC38 cells clearly show presence of (C) ERα66 and (D) ERα36 by 
western blot, while HCC38 only show presence of ERα36. 
 
 
Western blot analysis confirmed the presence of ERα36 in both MCF7 and 
HCC38 cell lines but not in COS7 cells, and ERβ was detected in lysates from MCF7, 
COS7, and HCC38 cells (Figure 3.1B). Because we are limited to using polyclonal 
antibodies to identify ERα66 separately from ERα36 in this study, and we noticed 
nonspecific bands above 100 kDa in blots of our unfiltered lysates, we performed 
Western analysis on filtered lysates to verify the specificity of the ERα36 antibody. This 
allowed us to look more closely at the recognition bands from 36 to 66 kDa. The 
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antibodies to ERα66 recognized three bands of varying intensity on blots of MCF7 cells 
but did not recognize a single band in HCC38 cells (Figure 3.1C). Polyclonal antibodies 
raised against the unique C-terminal end of ERα36 recognized two bands in MCF7 cells 
(Fig. 1C), but they only recognized a single band at ∼37 kDa in HCC38 cells (Figure 
3.1D). The presence of a second band in the MCF7 cell lysates does not appear to be 
ERα46 but more likely may be representative of a post-translationally modified form of 
ERα36. 
 
3.3.2 Rapid E2-induced PKC Activation in MCF7 and HCC38 Cells Occurs via 
Membrane Signaling through ERα36 
E2 caused a dose-dependent increase in PKC activity in MCF7 cells (Figure 
3.2A) and in HCC38 cells (Figure 3.2B) at 9 min. Antibodies to ERα36 completely 




Figure 3.2: E2 rapidly activates PKC in breast cancer cells through ERα36. 
E2-induces activation of PKC in MCF7 and HCC38 cells rapidly within 9 minutes of 
treatment (A,B). E2-induced rapid activation of PKC in MCF7 and HCC38 cells occurs 
through ERα36. E2 rapidly induces PKC activity within 9 minutes in both MCF7 and 
HCC38 cells and antibody blocking of ERα36 on the cells’ membranes abolishes this 
effect (C,D). * p<0.05 compared to 0M E2, $ p<0.05 compared to 10-9M E2, # p<0.05 
compared to IgG. 
 
 
3.3.3. PKC Maintains Cell Survival in HCC38 Cells 
Chelerythrine caused a dose-dependent decrease in MTT activity in HCC38 cells 
(Figure 3.3A), indicating decreased cell viability. In addition, chelerythrine caused a 
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dose-dependent increase in DNA fragmentation (Figure 3.3B), indicating that inhibition 




Figure 3.3: PKC activity is required to maintain cell survival. 
Inhibition of PKC with chelerythrine causes dose-dependent decreases in MTT (A) and 
dose dependent increases in DNA fragmentation (B). Phosphate, which induces 
apoptosis in other cell types such as chondrocytes, does not induce apoptosis in breast 
cancer cells. * p<0.05 compared to 0M chelerythrine, $ p<0.05 compared to 10-7M 
chelerythrine, # p<0.05 compared to 10-6M chelerythrine. 
 
 
3.3.4 E2-dependent Activation of PKC Requires Intact Caveolae 
Immunofluorescence of ERα-positive MCF7 cells showed that ERα66 and ERα36 
were differentially distributed. In MCF7 cells that were not permeabilized by detergent, 
ERα66 and ERα36 were both present on the plasma membrane (Figure 3.4A). When 
cells were permeabilized by Triton X-100, ERα66 was mainly localized peri-nuclearly. 
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ERα36 was primarily non-nuclear, but it was also distributed throughout the cells, 
although not to the same extent peri-nuclearly as ERα66. 
Confocal microscopy indicated that ERα36 co-localized with lipid rafts and 
caveolin-1 protein in both MCF7 and HCC38 cells (Figure 3.4B). Staining with antibodies 
to protein-disulfide isomerase, which is primarily found in the endoplasmic reticulum, 
showed that ERα36 did not co-localize to endoplasmic reticulum. Western blots detected 
ERα36 and caveolin-1 in pure caveolae fractions (F3) from both cell lines (Figure 3.4C). 
COX-IV was not found, demonstrating that the plasma membrane fractions were not 
contaminated with mitochondrial membranes. E2 did not stimulate PKC activity in HCC38 
cells after treatment with methyl β-cyclodextrin, which destroys caveolae (Figure 3.4D), 




Figure 3.4: Immunofluorescence shows that ERα66 primarily exhibits peri-nuclear 
localization in MCF7 cells, while ERα36 exhibits non-specific localization 
throughout the cells. 
Qualitatively, it appears that ERα36 exhibits greater cell surface expression than ERα66 
(A). ERα36 colocalizes with lipid rafts and caveolin-1 in both MCF7 and HCC38 cells and 
does not appear to localize to endoplasmic reticulum in either cell (B). Caveolae fraction 
of both MCF7 and HCC38 cells show the existence of ERα36 in caveolae (F3) (C) and 
digestion of cholesterol and removal of lipid raft and caveolae from the cell membranes 
of HCC38 cells by β-cyclodextrin (MeβCD) signify the requirement of caveolae for rapid 
signaling of E2 from the membrane (D). * p<0.05 compared to 0M E2, # p<0.05 
compared to 10-9M E2, $ p<0.05 compared to 10-8M E2. 
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3.3.5 Rapid E2 Signaling in HCC38 Breast Cancer Cells Protects Cells from Taxol-
induced Apoptosis through ERα36 while Enhancing Proliferation 
Treatment of HCC38 cells with taxol increased apoptosis (Figure 3.5, A–D). 
When cells were pretreated with E2, the apoptotic effects of taxol were reduced, based 
on decreases in TUNEL (Figure 3.5A) and caspase-3 activity (Figure 3.5B). The fact that 
E2-BSA also exhibited this effect (Figure 3.5, C and D) indicates that reduction of taxol-




Figure 3.5: Effect of estrogen on taxol-induced apoptosis. 
E2 and E2-BSA protected HCC38 cells against taxol-induced apoptosis as measured by 
TUNEL (A,B) and Caspase-3 activity (C,D). * p<0.05 compared to control + 0M E2, # 
p<0.05 compared to 20uM taxol + 0M E2, $ p<0.05 compared to control + 10-8M E2, • 
p<0.05 compared to control + 10-7M E2. 
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The proliferative effect of E2 also involved a membrane-associated mechanism. 
Both E2 and E2-BSA enhanced [3H]-thymidine incorporation in HCC38 cells (Figure 3.6, 
A and B). Treatment of the cultures with antibodies to ERα36 blocked this effect. In 





Figure 3.6: Effect of estrogen through ERα36 on cell proliferation. 
E2 (A) and E2-BSA (B) caused an increase in DNA synthesis as measured by [3H]-
thymidine incorporation, and when cells were pre-treated with antibody against ERα36, 
E2-BSA induced cell proliferation was inhibited. * p<0.05 compared to control + 0M E2, # 
p<0.05 compared to control + 10-8M E2 or 10-7M E2 or 10-7M E2-BSA. 
 
 
3.3.6 Estrogen Signaling through ERα36 Increases Expression of Factors That 
Can Enhance Cancer Cell Metastasis and Bone Resorption 
E2-BSA treatment of HCC38 cells caused increased expression of the metastatic 
factor Snail1, although pretreatment with antibody against ERα36 blocked this effect 
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(Figure 3.7A). At the same time, E2-BSA down-regulated e-cadherin (CDH1) (Figure 
3.7C) indicating that expression of factors associated with epithelial to mesenchymal 
transition may also be mediated by ERα36-dependent signaling. E2-BSA also had a 
stimulatory effect on CXCR4 expression (Figure 3.7E). We also saw an inhibitory effect 
of E2 and E2-BSA on syndecan-4 expression when normalized to GAPDH, but this was 
not blocked by antibodies to ERα36 (supplemental Figure A3.1). We did not see any 
effect of estrogen on MMP9 expression under these experimental conditions (data not 
shown). E2-BSA increased expression of the osteoclast activator RANKL by an ERα36-
dependent mechanism, based on inhibition of the effect by anti-ERα36 antibodies 
(Figure 3.7B). E2-BSA had no effect on osteoprotegerin production (Figure 3.7D). Levels 
of this RANKL decoy receptor remained unchanged. Interestingly, E2 treatment led to a 
slight decrease in osteoprotegerin levels (data not shown), potentially via a mechanism 




Figure 3.7: Membrane estrogen signaling via ERα36 enhances expression of 
factors that can enhance metastasis of breast cancer cells. 
qRT-PCR analysis indicates that E2 signaling in HCC38 cells increases expression of 
Snail1 (A) and a correlating downregulation of E-Cadherin expression is also observed 
(C). E2-BSA also upregulates expression of CXCR4, the chemokine receptor for SDF-1 
(E). E2-BSA signaling via ERα36 enhances expression of osteoclastogenic factors. qRT-
PCR analysis indicates that E2 signaling in HCC38 cells increases expression of RANKL 
through ERα36 at the membrane (B) with no observed change in OPG production (D), 
while IL-6 production is enhanced (F). * p<0.05 compared to control + 0M E2-BSA, # 
p<0.05 compared to control + 10-7M E2-BSA. 
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3.3.7 Estrogen Signaling through Membrane-associated ERα36 Promotes in vitro 
Invasiveness of HCC38 Breast Cancer Cells 
Using the scratch-wound method, we observed that E2-BSA treatment of HCC38 
cells caused more rapid closure of the wound created in a two-dimensional culture 
(Figure 3.8A). Furthermore, we found that treatment with antibody against ERα36 





Figure 3.8: Membrane estrogen signaling via ERα36 promotes invasiveness of 
breast cancer cells in vitro. 
Results of the scratch wound assay indicate that E2 signaling in HCC38 cells through 
membrane-associated ERα36 can lead to more rapid closure of the wound created in 
the culture. (A) shows select phase-contrast images of representative samples from 
control samples,  E2-BSA-treated samples, anti- ERα36-treated samples, and samples 
treated with both. (B) shows time course data of samples treated with increasing 




This study exhibits that ERα-negative HCC38 breast cancer cells do in fact 
express ERα36 and that rapid activation of PKC in these cells in response to E2 occurs 
through membrane-associated ERα36. It is unknown if ERα36 is expressed in all 
cancers; however, the findings presented in this article open the possibility that many 
ERα-negative breast cancers may actually express ERα36. In fact, the HCC38 cell line 
used in this study is triple-negative (57, 94), and therefore does not express PR or HER-
2, suggesting that triple-negative breast cancers may also express this specific splice 
variant of ER. Although MDA-MB-231 and SkBr3 breast cancer cells have been cited in 
the literature as ERα-negative (95), our results show that even these cells express 
ERα36, which further supports the claim that ERα36 has a function in ER-negative 
breast cancers. We did however see that the COS7 cell line did not contain protein for 
ERα36, but this may be due to the fact that this cell line is derived from a non-human 
primate and we can account for this based on inter-species differences as well as the 
fact that the cell line is of embryonic origin. 
GPR30 is a very well studied alternative receptor for estrogen that remains 
controversial as far as its subcellular localization is concerned(49, 82, 96, 97). We saw 
that all ER-negative cells, including HCC38 expressed GPR30 mRNA. This may suggest 
a role of GPR30 in ER-negative breast cancer, but our results here do not indicate a role 
for GPR30 in breast cancer cell proliferation. The fact that the antibody against GPR30 
did not block the effect of E2 nor E2-BSA on [3H]-thymidine incorporation is evidence that 
GPR30 does not mediate the membrane-associated response of ERα66-negative cells 
to E2, at least where cell proliferation is concerned. However, ERα36 is responsible for 
mediating breast cancer cell proliferation. We did observe that when cells were treated 
with estrogen and pre-treated with antibodies against GPR30, [3H]-thymidine 
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incorporation increased above baseline estrogen treatment. We can speculate that by 
blocking GPR30, we may be altering the kinetics of E2 signaling by allowing more E2 to 
be available for signaling through ERα36, but this requires more in depth analysis to 
come to this conclusion. 
The present study focused on non-traditional mechanisms of ERα36, as we were 
highly interested in the role that this protein plays in rapid membrane-initiated signaling. 
Our findings suggest that ERα66 plays a greater role in nuclear-receptor signaling than it 
does in the cytosol or membrane, while ERα36 may have functions more prevalent 
outside of the nucleus. Localization of ERα36 to caveolae within the cell membrane 
suggests that ERα36 plays a major role in rapid membrane-initiated signaling. Caveolae 
typically house several proteins that are involved in many rapidly activated membrane-
associated pathways (34, 86), such as those associated with vitamin D3 metabolites (37, 
98), testosterone, and especially estrogen (37). The loss of caveolae by β-cyclodextrin 
treatment indicates the requirement of caveolae for these membrane-specific responses 
of estrogen. Due to the complex nature of caveolae and the many proteins that may be 
found within caveolae, it is quite possible that ERα36 does not work alone in these 
pathways. 
As previously observed, we found that E2 rapidly activated PKC within minutes in 
both MCF7 and HCC38 cells. When we pretreated cells with antibodies that specifically 
target ERα36, the effects of E2 were completely abolished. When we account for the fact 
that in our previous study(57), we did not see inhibition of this PKC effect when we used 
antibodies to block ERα66, we can conclude that ERα36 is responsible for this effect, 
and this response is initiated from the membrane due to the fact that the antibodies 
cannot cross the membrane and are therefore targeting membrane associated 
receptors. 
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We have found that these rapid membrane-mediated effects are associated with 
enhanced breast cancer cell survival. The PKC pathway appears to be crucial to the 
anti-apoptotic effects of estrogen in these cells as evidenced by the effect of 
chelerythrine on MTT and DNA fragmentation. Because we did not observe cell death in 
response to phosphate treatment, yet we did when we inhibited PKC with chelerythrine, 
we can conclude that PKC plays a major role in breast cancer cell survival and 
tumorigenesis.   
One mechanism by which E2-dependent activation of PKC may function in cell 
survival is by promoting cell proliferation. We previously demonstrated that the addition 
of tamoxifen, an antagonist of the estrogen receptor, which actually inhibits PKC in 
breast cancer, caused inhibition of DNA synthesis in MCF7 and HCC38 breast cancer 
cells(57). Together with data from Marino et al. showing that estradiol increases DNA 
synthesis through PKC activation (99), our observations support this hypothesis.   
In addition, numerous studies(100-104), including a previous study by our 
group(57), have implicated PKC signaling as a major contributor to tumor progression. 
We found a strong correlation among PKC activity and tumor size and recurrence, which 
contained well over 100 subjects. This observation indicated that patients diagnosed as 
ER-negative according to the current screening method may in fact respond to 
tamoxifen.   
Because we observed that tamoxifen inhibits PKC through this specific pathway 
of E2, we decided to observe E2’s effects on different pathways of other 
chemotherapeutics, such as taxol. Our results indicate that not only does E2 enhance 
cell survival by increasing cell proliferation through this membrane-mediated 
mechanism, as evidenced by effects of E2-BSA, but E2 also elicits anti-apoptotic effects 
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on these cells that can oppose the effects of very commonly used chemotherapeutic 
agents, such as taxol. Enhancement of cell proliferation in conjunction with the anti-
apoptotic effects of E2 can be implicated in primary aggressive tumor growth. The ability 
of estrogen to counteract the effects of taxol in these breast cancer cells poses a great 
problem in the treatment of the disease. 
The progression of a tumor and development of metastasis is a very complex 
process. As the tumor continues to grow, the intracellular signaling of local factors 
associated with angiogenesis alleviates the requirement of a neo-vasculature. 
Expression of several factors such as Snail1 and Snail2 leads to a down-regulation of 
cell-cell interaction proteins such as cadherins, leading to what is known as an epithelial 
to mesenchymal transition(105-107). This alteration in cancer cell phenotype imparts the 
ability of the cells to detach from the primary tumor and migrate to distant sites of the 
body. Breast, as well as prostate cancer, appear to have a particular affinity for 
metastasizing to osseous tissue (90), which indicates poor prognosis for the patient. The 
effect of estrogen on RANK ligand in our system indicates the possibility that estrogen 
signaling within the primary breast tumor can enhance secretion of factors by the tumor 
inducing osteoclastogenesis, thereby promoting bone remodeling. This can create a 
“fertile” soil for the attachment of migrating cancer cells and because bone is so highly 
vascularized (90), the probability of migrating cancer cells to find a location in bone on 
which to attach and form metastases is extremely high. Increases in chemotactic 
receptors such as CXCR4, as we observed; also promote migration to sites where 
ligands for this receptor, such as SDF-1, reside in high levels. In addition, effects of 
estrogen on extracellular matrix interacting components, such as membrane syndecan-
4, can also promote detachment of cancer cells from the primary tumor.  
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Our results suggest that many breast cancer cell responses to estrogen include 
upregulation of many of these factors, and the fact that ERα36 directly mediates these 
responses, as well as promoting in vitro invasiveness, suggests that this receptor may 
play a major role in breast cancer metastasis. ERα36 has even been shown to have a 
high association with lymph node metastasis in subjects with gastric cancer (108). 
Because ERα36 does retain the DNA-binding domain found in traditional ERα, it 
is still possible that this receptor may play some role in directly regulating gene 
expression; however, the fact that it does not retain either transcriptional activation 
domains (AF1/AF2) suggests that it may only function as a co-factor for transcription or 
even as a transcriptional repressor. This suggests that ERα36 may play multiple roles in 
regulating cell differentiation and survivability. Taking this into account with data showing 
different effects of estrogen signaling through ERα36 in rat costochondral resting zone 
chondrocytes(109), the possibility remains that ERα36 also plays different roles 
depending on the cell type, especially whether the cells are cancerous or not. 
From our previous data on estrogen signaling in MCF7 and HCC38 breast 
cancer cells and with our current findings, we hypothesize that E2 interacts with ERα36 
at the cell membrane to rapidly activate PKC through a PI-PLC-dependent mechanism 
that cleaves PIP2 to IP3 and DAG. IP3 promotes calcium influx from the smooth 
endoplasmic reticulum while DAG helps to anchor PKC to the cell membrane, thereby 
promoting activation of PKC. Because PKC can activate ERK1/2 (80), which can rapidly 
enhance phosphorylation of proteins that promote proliferation, as well as factors that 
may enhance downstream gene expression, this pathway may lead to indirect effects on 
gene expression. This can be inhibited by chelerythrine, which directly inhibits PKC. 
Genes that may be affected, such as RANKL and Snail1, can promote metastatic activity 
of the breast cancer cells. These responses that can rapidly activate ERK1/2 can lead to 
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diverging pathways by which PIP2 cleavage can also enhance anti-apoptotic effects of 
E2 possibly through activation of Akt. Taxol has been shown to activate apoptosis of 
breast cancer cells by enhancing activity of c-Jun kinase (JNK), which alters the ratio of 
the Bcl-2 family of proteins such as Bax (pro-apoptotic) and BAD (anti-apoptotic), which 
in turn leads to enhanced permeability of the mitochondrial membrane and release of 
cytochrome C(69). This eventually leads to activation of the apoptotic caspase cascade, 
eventually leading to activation of caspase-3 and apoptosis. This study has specifically 
shown that membrane-associated estrogen signaling can inhibit taxol-induced caspase-






Figure 3.9: Proposed model of rapid membrane-initiated signaling of estrogen via 
ERα36. 
E2 interacts with ERα36 at the cell membrane initiating a signaling cascade consisting of 
phosphatidylinositol-specific phospholipase C (PI-PLC) dependent cleavage of 
phosphatidylinositol bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol 
(DAG). IP3 signals Ca2+ release from the smooth endoplasmic reticulum, while DAG 
anchors protein kinase C (PKC) to the membrane. The membrane localization along with 
Ca2+ association with PKC leads to its activation, which can be inhibited by chelerythrine, 
with downstream activation of ERK1/2 mitogen activated protein kinase (MAPK). 
Activation of ERK1/2 can affect cell proliferation as well as phosphorylation of 
transcription factors that can activate or repress gene transcription, possibly leading to 
expression of factors associated with metastasis and tumor aggressiveness. Taxol 
induces apoptosis through a mechanism involving JNK MAPK and the Bcl2-associated 
proteins Bax and BAD, leading to release of cytochrome C from the mitochondria. This 
initiates the caspase cascade involving caspases-9 and -7, eventually leading to 
activation of caspase-3, which causes apoptosis. E2 signaling through membrane-
associated receptor prevents taxol-induced apoptosis through a mechanism that may 




The findings of this article present a novel target for development of new 
therapies such as pharmaceutical intervention against progression of breast cancer 
primary tumor growth and prevention of metastasis. The mechanism of the membrane 
receptor for estrogen in breast cancer tumorigenesis and metastasis has not been 
previously reported. This study identifies a membrane receptor for estrogen in breast 
cancer cells that activates an array of pathways. We show that estrogen signaling via 
ERα36 initiated at the cell membrane activates cross-talk among multiple pathways 
important for breast cancer aggressiveness. Figure 3.9 proposes a model for the 
mechanism by which membrane estrogen signaling through ERα36 enhances cell 
proliferation, anti-apoptotic effects, and metastatic effects. A drug that specifically targets 
the membrane-associated estrogen receptor, ERα36, may not pose harmful effects on 
normal estrogen processes that occur within the cells, as ERα36 cannot activate 
expression of genes containing traditional estrogen response elements (EREs). A multi-
faceted approach to treatment remains necessary as cancer, especially breast cancer, 
exemplifies a class of diseases rather than a single disease. Every patient is unique, but 
further investigation and understanding of membrane-associated signaling of estrogen in 
breast cancer can possibly lead to new routes of treatment for this devastating disease. 
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CHAPTER 4: ERα36 Mediates the Anti-apoptotic Effect of Estradiol in Triple 




[Chapter 4 has been prepared for manuscript submission as: Chaudhri RA, Hadadi A, 
Lobachev KS, Boyan BD, Schwartz Z. The Mechanism by which ERα36 Mediates the 




Estrogen receptor (ER)-positive breast cancer typically responds to anti-estrogen 
treatment as estrogen enhances cell proliferation and tumor growth. However, previous 
work has shown that some ER-negative breast cancers respond to 17b-estradiol and 
anti-estrogens such as tamoxifen. Not only do these cancers respond to 17b-estradiol, 
but also the effect is rapid and non-genomic, suggesting that these effects can be 
mediated by the presence of a membrane-associated ER. ERα36 has been shown to 
mediate rapid, non-genomic, membrane-associated effects of 17b-estradiol in several 
cancer cell lines, including ER-negative HCC38 breast cancer cells. Moreover, the effect 
of 17b-estradiol in these cells is anti-apoptotic. The aim of this study was to determine if 
ERα36 mediates this anti-apoptotic effect, and to elucidate the mechanism involved. 
Taxol was used to induce apoptosis in HCC38 cells, as indicated by increased caspase-
3 activity, and the effect of 17b-estradiol pre-treatment was determined. Antibodies to 
ERα36, inhibitors to specific cell signaling molecules, ERα36 deletion mutants, and 
ERα36-silencing were used prior to these treatments to determine the role of ERα36 in 
these effects and to determine which signaling molecules were involved. We found that 
the anti-apoptotic effect of 17b-estradiol in HCC38 breast cancer cells is in fact mediated 
by membrane-associated ERα36. We also showed that this signaling occurs through a 
pathway that requires PLD, LPA, and PI3K; Gαs and calcium signaling may also be 
involved. In addition, dynamic palmitoylation is required for the membrane-associated 
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effect of 17b-estradiol. Exon 9 of ERα36, a unique exon to ERα36 not found in other 
identified splice variants of ERα with previously unknown function, is necessary for these 
effects. This study provides a working model for the mechanism by which estradiol 
promotes anti-apoptosis through membrane-associated ERα36, suggesting that ERα36 
may be a potential membrane target for drug design against breast cancer, particularly 
triple negative breast cancer. 
 
4.1 INTRODUCTION 
Breast cancer is the most common non-cutaneous cancer among women in the 
United States. The National Cancer Institute estimates that there will be 232,340 new 
cases among women in the U.S. in 2013, which correlates to about 1 in 8 women 
receiving diagnosis. The NCI also predicts 39,620 deaths due to breast cancer in the 
same year. Although the 5-year survival for patients diagnosed in the early stages of 
breast cancer exceeds 90%, survival in patients with distant metastasis drops below 
25% indicating very poor prognosis for these individuals (5). While an actual cure for 
breast cancer is elusive, novel approaches to diagnosis and treatment can help to 
reduce mortality and allow patients, specifically those with more advanced stage cancer, 
to live normal lives. 
The progression of cancer is a dynamic process that begins with primary tumor 
growth, depending on cancer cell proliferation simultaneously with the ability of cancer 
cells to evade apoptosis (110). In some cases, aggressive cancer cells can evade 
apoptosis even in the presence of radiotherapy and chemotherapeutic drugs that are 
used to target these cells and specifically induce apoptosis (69, 88). Current approaches 
to treatment have evolved to combination therapy, usually beginning with surgery and/or 
targeted radiotherapy, followed by adjunctive chemotherapy (111-113). 
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Taxol, a very commonly used chemotherapeutic drug, is the first of a group of 
drugs known as taxanes, which induce apoptosis in cells by inhibiting mitosis (114, 115). 
Currently, taxol is synthetically prepared and various formulations and carriers are being 
developed to increase the effectiveness of the drug (116). Moreover, the main problem 
with drugs such as taxol is that they do not only target cancer cells, but can also induce 
apoptosis in normal cells (117, 118). This necessitates current approaches of targeted 
therapy, by which newer targets are being discovered that are either unique or highly 
upregulated in cancer cells. 
Estrogen receptors (ERs) play a major role in classification, diagnosis, and 
treatment of breast cancer (119-121). Patients that contain hormone responsive or ER-
positive tumors are expected to take the ER-agonist tamoxifen continuously for 5 years 
following initial treatment (122). Tamoxifen functions as an anti-estrogen, and we 
previously showed that it could block the stimulatory effect of 17b-estradiol (E2) on ER-
negative breast cancer cells as well as in ER-positive cells (57). Traditional inhibitors of 
ERs, such as ICI 182,780 and diethylsilbesterol, did not block E2-induced cell 
proliferation or protein kinase C (PKC) activity in the ER-negative cells, nor did traditional 
antibodies to ERα and ERβ (57).  
Membrane-associated E2 signaling also elicits anti-apoptotic effects against taxol, 
leading to an aggressive cancer phenotype (54, 69). Taxol induces apoptosis through a 
c-Jun N-terminal kinase (JNK)-dependent mechanism that promotes mitochondrial efflux 
of cytochrome C, leading to activation of an apoptotic caspase cascade (69). This 
suggests that receptor-mediated signaling is involved, but traditional ERα is not 
responsible.  
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We recently showed that ERα36, an alternatively spliced variant to traditional 
ERα, is responsible for the membrane-mediated effect of E2 in breast cancer cells that 
promotes cell survivability (54). The mRNA of ERα36 lacks the first exon found in 
traditional ERα, ERα66, as well as exons 7 and 8 (53). This results in a truncated form of 
ERα66 that does not contain the transcriptional activation domains AF1 and AF2 and a 
truncated ligand-binding domain, however, ERα36 still exhibits ligand-dependent effects 
of E2 (53, 55, 123). In addition, ERα36 contains a novel exon at the C-terminus known as 
exon 9. This exon contains 27 amino acids of unknown function, but it is hypothesized to 
contain myristolation or palmitoylation-specific sequences (53, 124), which would help to 
explain any membrane-associated effects mediated by ERα36. This study investigated 
the mechanism by which ERα36 prevents taxol-induced apoptosis. We hypothesized 
that ligand-dependent activation of ERα36 induces receptor-dependent inhibition of 
signaling cascades associated with activation of apoptosis, as well as activation of anti-
apoptotic signaling cascades. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Reagents 
ERα-negative HCC38 human breast cancer cells and human embryonic kidney 
HEK293 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). Roswell Park Memorial Institute 1640 medium (RPMI 1640) was 
purchased from Invitrogen (Grand Island, NY). Charcoal/dextran-filtered fetal bovine 
serum (FBS) was purchased from Gemini Bioproducts (Sacramento, CA). E2 enantiomer 
(Ent-E2) was kindly provided as a gift from Dr. Douglas Covey (Washington University, 
St. Louis, MO) (125). E2, E2-BSA, taxol, 2-hydroxymyristic acid (HMA), 2-
bromohexadecanoic acid (2-bromopalmitate, 2-BP), and tunicamycin (Tm) were 
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purchased from Sigma (St. Louis, MO). Cycloheximide (CHM), Wortmannin, D609, 
U73122, LY294002, thapsigargin, pertussis toxin (PTX), and cholera toxin (CTX) were 
purchased from EMD Chemicals (Gibbstown, NJ). VPC32183S and lysophosphatidic 
acid (LPA) were purchased from Avanti Polar Lipids (Alabaster, AL). Protein content of 
samples was measured using the Macro BCA reagent kit from Pierce/Thermo Scientific 
(Rockford, IL). Polyclonal ERα36 antibodies against the unique C-terminal 27 amino 
acids were generated by Cell Applications Inc. (San Diego, CA). 740 Y-P and the 
Titertacs TUNEL assay were purchased from R&D Systems (Minneapolis, MN). Goat 
anti-rabbit horseradish peroxidase (HRP) and goat anti-mouse HRP-conjugated 
secondary antibodies were obtained from Bio-Rad (Hercules, CA). Bax and Bcl2 primers 
were purchased from Eurofins MWG Operon (Huntsville, AL). The cytochrome C 
apoptosis assay kit was purchased from MBL International (Woburn, MA). The Amplex 
Red Phospholipase D (PLD) Assay kit was purchased from Life Technologies (Grand 
Island, NY). Caspase-3 activity was measured using the CaspAce Assay system from 
Promega (Madison, WI). ERα36 overexpression plasmids were purchased from Chi 
Scientific (Maynard, MA). Polyfect transfection reagent was obtained from Qiagen 
(Germantown, MD). 
 
4.2.2 Cell Culture 
HCC38 cells and HEK293 cells were cultured in RPMI 1640-based media or 
DMEM, respectively, as specified by the ATCC containing 10% charcoal/dextran-filtered 
FBS and lacking phenol red, which can mimic the effects of E2 at low levels (126, 127). 
Specific modifications for each experimental question are described below. 
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4.2.3 Requirement for ERα36 in E2’s Anti-apoptotic Effect 
 
4.2.3.1 Apoptotic Effect of Taxol in HCC38 Cells 
The experimental design for this study was based on the ability of E2 to block the 
apoptotic effects of taxol. Initial experiments were performed to establish the effect of 
taxol on HCC38 cells. 24 hours after plating, HCC38 cells were treated with increasing 
concentrations of taxol (5, 10, 20µM) for 4 hours, after which TUNEL and caspase-3 
activity were measured using assays kits according to the manufacturers’ directions. To 
confirm that the effects of taxol were apoptotic, as caspase-3 activity is implicated in the 
terminal differentiation of some cell types (128-131), HCC38 cells were treated with 
20µM taxol for 12 hours and BAX/BCL2 mRNA levels were determined and cytochrome 
C translocation from the mitochondria to the cytosol was examined by the cytochrome C 
apoptosis assay kit from MBL International according to the manufacturer’s instructions. 
 
4.2.3.2 Requirement for a Receptor-mediated Membrane-associated Mechanism 
 E2 conjugated to bovine serum albumin (E2-BSA), which cannot cross the plasma 
membrane (21, 49, 132) was used to verify that the anti-apoptotic effect of E2 was via a 
membrane-mediated mechanism. E2-BSA has previously been shown to have similar 
effects to E2 and can interact with ERs. BSA conjugation prevents E2 from crossing the 
plasma membrane, and therefore, E2-BSA effects can be attributed to either membrane 
receptor effects or alterations in membrane fluidity due to it’s the hydrophobic nature of 
E2-BSA (49, 57, 132, 133). To address the possibility that E2’s effect is due to a non-
specific interaction with the plasma membrane, cells were also treated with the E2 
enantiomer Ent-E2 (125). While Ent-E2 is an enantiomer of E2, it cannot directly interact 
with ERs, and therefore, any effects caused by Ent-E2 could be attributed to its direct 
effect on membrane fluidity as it possesses the same hydrophobic properties of E2.  
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 PLD activity was determined as an outcome measure, based on our previous 
observation that the anti-apoptotic effect of the vitamin D3 metabolite 24R,25-
dihydroxyvitamin-D3 (24,25(OH)2D3) occurs through activation of PLD (68). PLD activity 
was measured using the Amplex Red PLD assay from Life Technologies. Subconfluent 
cultures of HCC38 cells in 24-well TCPS plates were treated with E2 or Ent-E2. Also, 
prior to E2 treatment, a 15 minute pretreatment of cells with ERα36 specific antibodies 
(1:500 dilution) was performed to block the membrane receptor in order to determine if 
the effect of E2 was through membrane-associated ERα36. While antibodies cannot 
enter the cells, any inhibition of E2’s effect in the presence of antibody could be attributed 
with E2’s direct interaction with membrane-associated ERα36. 
 
4.2.3.3 ERα36 Silencing, Overexpression, and Mutation 
In order to confirm the role of ERα36 in the anti-apoptotic effect of E2, HCC38 
cells were transiently transfected with an ERα36 shRNA expression plasmid in order to 
transiently knockdown ERα36. The shRNA expression plasmid was produced by cloning 
a microRNA specific anti-sense target sequence for the 3’UTR of ERα36 cDNA using the 
DNA oligonucleotides, 5’-GGATCCCATGCCAATAGGTACTGAATTGATATCCGTTCAG-
-TACCTATTGGCATTTTTTTCCAAAAGCTT-3’, and was prepared by Sigma-Aldrich 
using their Mission shRNA purified plasmid expression system. HCC38 cells were 
seeded at a density of 1.25 x 105 cells/cm2 in tissue culture treated polystyrene (TCPS) 
and cultured in media containing no antibiotics. One day after plating, when cells were 
approximately 75% confluent, transient transfection was performed using Polyfect 
transfection reagent from Qiagen according to the manufacturer’s instructions. Media 
were changed after 24 hours to full growth media, and 48 hours after transfection, cells 
were treated according to experimental procedures. The PLD and caspase-3 activity 
assays were performed with HCC38 silenced for ERα36 (denoted as shERα36), wildtype 
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HCC38 cells (denoted as wt), and mock transfected HCC38 cells. Whole cell lysates 
were harvested in RIPA and western blot was performed on wt and shERα36 HCC38 
cells using ERα36 antibodies (1:500 dilution). Densitometry analysis using Quantity One 
software was performed to determine percentage of knockdown in shERα36 cells. 
In order to determine the importance of ERα36 on a more generalized platform, 
the human embryonic kidney cell line, HEK293, which has been previously 
demonstrated to not express functional levels of endogenous ERα36 (55), was used as 
a model for analysis of wildtype exogenous ERα36 overexpression (denoted as 
293ovrx36). Use of HEK293 cells thus allowed us to examine the role of wildtype 
exogenous ERα36 and mutated ERα36 independent of the presence of functional 
endogenous ERα36. 
Because exon 9 is unique to ERα36, and ERα66 has not been shown to mediate 
the membrane-associated effect of E2 in ER-positive MCF7 cells (57), we hypothesized 
that exon 9 was required for these responses. An exon 9 deletion mutant (denoted as 
293ex9d36) was created using overlap extension PCR cloning as previously described 
by Bryksin and Matsumura (134). Exon 9 deleted HEK293 cells were then created 
according to the methods described below, allowing us to examine the requirement of 
this exon in the anti-apoptotic pathway of E2. 
HEK293 cells were transiently transfected with ERα36 wt overexpression and 
exon 9-deletion plasmids using Polyfect transfection reagent according to 
manufacturer’s instructions. HEK293 cells were seeded at a density of 1.25 x 105 
cells/cm2 in TCPS plates and cultured in medium containing no antibiotics. One day after 
plating, when cells were approximately 75% confluent, transient transfection was 
performed using Polyfect transfection reagent according to the manufacturer’s protocol. 
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Media were changed after 24 hours to full growth media, and 48 hours after transfection, 
cells were treated as previously described for measurement of PLD and caspase-3 
activity. PLD and caspase-3 activity assays were performed in HEK293 overexpressed 
with wildtype ERα36 (293ovrx36) and exon 9-deleted ERα36 (293ex9d26). Wildtype 
HEK293 cells mock transfected with a non-targeting vector and plated at the same time 
as the mutant cells were used as positive controls. Whole cell lysates were harvested in 
RIPA and western blot was performed on 293wt, 293ovrx36, and 293ex9d36 HEK293 
cells using ERα antibodies (1:500 dilution) that can also detect ERα36. These antibodies 
were used rather than ERα36 antibodies because the ERα36 antibodies detect the C-
terminal domain of ERα36, and the exon 9 deletion mutants (293ex9d36) do not contain 
this region. Bands shown in western blots were detected at ~36kDa. Densitometry 
analysis using Quantity One software was performed to determine percentage of 
knockdown in shERα36 cells. 
 
4.2.3.4 Examination of E2’s Anti-apoptotic Pathway 
In order to determine the signaling pathway involved in the anti-apoptotic effect of 
E2, we took advantage of the observation that E2 inhibits taxol-induced apoptosis via 
membrane-associated signaling by attenuating the effect of taxol on caspase-3 activity 
(54, 69). For the experiments described below, subconfluent cultures of HCC38 cells 
were pretreated with 10-8M E2 for 90 minutes followed by 20µM taxol treatment, after 
which time, E2 was removed from the cultures. After 24 hours of taxol treatment, he 
number of viable cells was determined by the MTT assay, which measures the reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to purple formazan by 
mitochondrial reductase in living cells (135). After 4 hours of taxol treatment, caspase-3 
activity was determined as described above. Requirement for ERα36 was determined by 
pretreating the HCC38 cells with antibodies generated against the unique C-terminus of 
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ERα36. Phosphatidylcholine-specific PLD (PC-PLD) was inhibited using 10-5M 
wortmannin (136, 137). Phosphatidylcholine-specific phospholipase C  (PC-PLC) was 
inhibited using 5x10-5M D609 (76, 137). Phosphatidylinositol-specific phospholipase C  
(PI-PLC) was inhibited using 10-5M U73122 (136, 137). 10-6M VPC32183S was used to 
block lysophosphatidic acid (LPA) signaling through LPA1 and LPA3 receptors, while 
LPA was used to activate LPA signaling (68). 10-5M LY294002 was used to block 
phosphoinositide-3-kinase (PI3K) (68). 10-6M 740 Y-P was used to activate PI3K 
signaling (138). 3µM thapsigargin was used to inhibit calcium translocation from the 
rough endoplasmic reticulum to the cytosol. Pertussis toxin (25ng/mL) was used to 
inhibit Gαi signaling, while cholera toxin (100ng/mL) was used to inhibit Gαs signaling 
(68). E2-BSA was also used in several of these experiments to further determine if these 
effects were membrane-associated. As previously described, E2-BSA cannot cross the 
plasma membrane, but still has many similar effects to E2. For all caspase-3 
experiments using E2-BSA, subconfluent cultures of HCC38 cells were pretreated as 
with the inhibitors stated above followed with 10-8M E2-BSA for 90 minutes. 20µM taxol 
was then added, and after 4 hours of taxol treatment, caspase-3 activity was measured 
as described above.  
 
4.2.3.5 Requirement for Dynamic Palmitoylation 
Previous work has shown that ER’s, particularly the ERα variants ERα66 and 
ERα46, can be targeted to the plasma membrane by palmitoylation (39, 139). ERα66 
and ERα46 have been identified as translocating to the plasma membrane due to 
palmitoylation. In order to examine this, tunicamycin and 2-bromohexadecanoic acid (2-
bromopalmitate, 2-BP) were used to inhibit palmitoylacetyltransferase and thus prevent 
palmitoylation of ERα36 (39). Cycloheximide (8µM) was used to block N-glycosylation 
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and HMA (0.5mM) was used to block myristolation (39). HCC38 cells were pre-treated 
with 30µM tunicamycin (Tm) and 10µM 2-BP to inhibit the activity of 
palmitoylacetyltransferase, which is responsible for post-translational palmitoylation of 
proteins that are targeted to the plasma membrane (39, 140). Tunicamycin, however, 
also inhibits N-linked glycosylation (39), and because of this, we also pre-treated cells 
with 8µM cycloheximide (CHM) as a control for N-glycosylation inhibition (39). In order to 
invalidate the possibility that the membrane effects of E2 through ERα36 do not occur 
due to myristolation, we also pre-treated cells with 0.5mM 2-hydroxymyristic acid (HMA), 
which blocks post-translational myristolation (39). In order to determine if palmitoylation 
of ERα36 is necessary for the anti-apoptotic effect of E2, HCC38 cells were pre-treated 
with 30µM Tm and 10µM 2-BP for 2 hours prior to E2 and taxol treatment for 4 hours, 
after which, caspase-3 activity was measured.  
 
4.2.4 Statistical Analyses 
For all experiments, statistical analyses were performed by analysis of variance 
with Bonferroni's correction for multiple comparisons at a significance level of 0.05. All 
experiments were performed with n=6 individual cultures per variable. Experiments were 
performed multiple times to ensure validity of the data. Results of individual experiments 
are presented. Identification of symbols to signify statistical significance is found in the 





4.3.1 Effect of Taxol on Apoptosis 
Taxol induced apoptosis in the HCC38 cells. Terminal deoxynucleotidyl 
transferase dUTP nick-end labeling (TUNEL) and caspase-3 activity both exhibited a 
dose-dependent increase (Figure 4.1A,B). BAX/BCL2 also increased, confirming that the 
cells were apoptotic (Figure 4.1C). Results were further confirmed by an increase in 
cytochrome C translocation from the mitochondria to the cytosol in the presence of 20µM 





Figure 4.1: Effect of taxol on apoptosis of HCC38 cells 
(A) Taxol’s (0, 5, 10, 20µM) effect on TUNEL and (B) caspase-3 activity is dose-
dependent. (C) Taxol also increased bax/bcl2 mRNA levels and (D) cytochrome C levels 
in the cytosol versus the mitochondria. Data is represented by the mean of 6 individual 
samples and error bars represent standard error of the mean. * represents p<0.05 




4.3.2 Role of ERα36 in Activation of PLD by E2 
We found that 10-8M E2 activated phospholipase D (PLD) in HCC38 cells at 30 
and 60 minutes (Figure 4.2A). The effect was receptor-mediated. Unlike E2, E2 
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enantiomer (Ent-E2) concentrations used in this study did not have the same effect at 30 
minutes (Figure 4.2B). Antibodies to ERα36 blocked the effect of E2 on PLD activity 
(Figure 4.2C). Additionally, E2 was unable to increase PLD activity in HCC38 cells 





Figure 4.2: Role of ERα36 in the Effect of E2 on Phospholipase D Activity 
(A) Time course study of the effect of E2 on PLD activity in HCC38 cells. (B) Dose 
dependent effect of E2 on PLD activity after 30 minutes in HCC38 cells. Ent-E2 showed 
no ability to enhance PLD at any concentration. (C) ERα36 inhibits the effect of 10-8M E2 
on PLD activity after 30 minutes. (D) Transient transfection of HCC38 cells with ERα36 
shRNA expression plasmid blocks the effect of E2 on PLD activity after 30 minutes. Data 
is represented by the mean of 6 individual samples and error bars represent standard 
error of the mean. * represents p<0.05 compared to the corresponding untreated control 
group while # represents p<0.05 compared to E2-treatment. 
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4.3.3 Role of ERα36 in the Anti-apoptotic Effect of E2 
Membrane activation of ERα36 signaling by E2 caused the anti-apoptotic effect of 
E2 against taxol. E2 blocked taxol-induced effects on MTT and caspase-3 activation 
while the antibody to ERα36 prevented the effect of E2 (Figure 4.3A,B) and E2 
conjugated to bovine serum albumin (E2-BSA) (Figure A4.1). Additionally, HCC38 cells 
transiently transfected with ERα36 shRNA expression plasmids (shERα36), with greater 
than 70% knockdown (Figure A4.2A), exhibited a reduced ability of E2 to block taxol-








Figure 4.3: Role of ERα36 in the Anti-apoptotic Effect of E2 
(A) MTT is reduced by 20µM taxol, while this effect is prevented by 10-8M E2. ERα36 
antibodies block this effect of E2. (B) Taxol-induced (20µM) caspase-3 activity is reduced 
by 10-8M E2, while ERα36 antibodies block this effect. (C) While E2 inhibits taxol-induced 
caspase-3 activity in wildtype HCC38 cells, HCC38 cells transiently transfected with 
shERα36 expression plasmids did not show the same effect. Data is represented by the 
mean of 6 individual samples and error bars represent standard error of the mean. * 
represents p<0.05 compared to the untreated control group while # represents p<0.05 





4.3.4 Role of Exon 9 
HEK293 cells transiently transfected with wildtype ERα36 cDNA expression 
vectors and mutant vectors designed to express exon 9-deleted ERα36 cDNA were 
shown to have greater detectable levels of ERα36 protein compared to wildtype HEK293 
cells, which exhibited very low levels of ERα36 shown by western blot using ERα 
antibodies that detect ERα36 (Figure A4.2B). Although wildtype HEK293 cells exhibited 
decreased PLD activity after 30 minutes of treatment with 10-8M E2, HEK293 cells 
transiently overexpressing exogenous wildtype ERα36 (293ovrx36) exhibited increased 
PLD activity after 30 minutes of E2 treatment. Exon 9-deleted exogenous ERα36 
expression mutants (293ex9d36) were unable to promote this effect of E2 on PLD activity 
(Figure 4.4A). Additionally, while overexpression of wildtype ERα36 allowed E2 to block 
taxol-induced caspase-3 activity in HEK293 cells, exon 9 deletion did not mediate E2’s 
effect against taxol induced caspase-3 activity. Interestingly, exon 9 deletion increased 







Figure 4.4: Requirement of Exon 9 in the Anti-apoptotic Effect of E2 
(A) PLD activity is reduced with 10-8M E2 wildtype HEK293 cells, while E2 increases PLD 
activity in ERα36 overexpressed HEK293 cells. In cells overexpressing exon 9-deleted 
ERα36, E2 did not exhibit this effect. * represents p<0.05 compared to the corresponding 
untreated control group. (B) Similarly, ERα36 overexpression mediated the anti-
apoptotic effect of E2 against taxol-induced caspase-3 activity, but in cells with exon 9-
deleted ERα36, this effect was not evident. * represents p<0.05 compared to the 
corresponding untreated 293wt, # represents p<0.05 compared to taxol only in 293wt, $ 
represents p<0.05 compared to untreated 293ovrx36, and @ represents p<0.05 




4.3.5 Role of PLD 
We also found that inhibition of phosphatidylcholine specific PLD (PC-PLD) with 
wortmannin blocked the anti-apoptotic effect of E2 on taxol-induced caspase-3 activity 
(Figure 4.5A), indicating that the effect of E2 on PLD leads to its anti-apoptotic effect. We 
did not see a similar effect when we inhibited phosphatidylcholine specific phospholipase 
C (PC-PLC) with D609 (Figure 4.5B) or phosphatidylinositol specific PLC (PI-PLC) with 
U73122 (Figure 4.5C), nor in the case of E2-BSA’s effect on taxol-induced caspase-3 





Figure 4.5: Role of Phospholipases in the Anti-apoptotic Effect of E2 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2, while wortmannin 
blocks this effect. (B) D609 and (C) U73122 do not exhibit the same effect as 
wortmannin. Data is represented by the mean of 6 individual samples and error bars 
represent standard error of the mean. * represents p<0.05 compared to the untreated 
control group while # represents p<0.05 compared to 20µM taxol and $ represents 




4.3.6 Role of Lysophosphatidic Acid 
The anti-apoptotic pathway of E2 was mediated by lysophosphatidic acid (LPA) 
signaling. When LPA signaling through the LPA1/3 receptors was inhibited with 
VPC32183S, the anti-apoptotic effect of E2 and E2-BSA on taxol-induced caspase-3 
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activity was prevented (Figure 4.6A, Figure A4.4A). VPC32183S also inhibited the effect 
of taxol (Figure 4.6A), suggesting some crosstalk in the taxol and E2 pathways. LPA 
blocked the effect of taxol on caspase-3 activity in a similar manner as E2 (Figure 4.6B). 
 
4.3.7 Role of Phosphoinositide-3-kinase 
Phosphoinositide-3-kinase (PI3K) plays a role in the anti-apoptotic pathway of E2. 
Inhibition of PI3K with LY294002 prevented the effect of E2 and E2-BSA on taxol-induced 
caspase-3 activity (Figure 4.6C, Figure A4.4B). Conversely, the PI3K activator 740 Y-P 








Figure 4.6: Role of LPA and PI3K in the Anti-apoptotic Effect of E2 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2, while the LPAR1/3 
antagonist, VPC32183S, does not allow E2 to block the effect of taxol. Data is 
represented by the mean of 6 individual samples and error bars represent standard error 
of the mean. * represents p<0.05 compared to the untreated control group while # 
represents p<0.05 compared to 20µM taxol and $ represents p<0.05 compared to 
inhibitor alone. (B) Taxol-induced (20µM) caspase-3 activity is reduced by LPA. Data is 
represented by the mean of 6 individual samples and error bars represent standard error 
of the mean. * represents p<0.05 compared to the untreated control group while # 
represents p<0.05 compared to 20µM taxol. (C) Taxol-induced (20µM) caspase-3 
activity is reduced by 10-8M E2, while the LY294002 does not allow E2 to block the effect 
of taxol. Data is represented by the mean of 6 individual samples and error bars 
represent standard error of the mean. * represents p<0.05 compared to the untreated 
control group while # represents p<0.05 compared to 20µM taxol and $ represents 
p<0.05 compared to inhibitor alone. (D) Taxol-induced (20µM) caspase-3 activity is 
reduced by the PI3K activator 740 Y-P. Data is represented by the mean of 6 individual 
samples and error bars represent standard error of the mean. * represents p<0.05 






4.3.8 Effect of Calcium and G-protein Signaling 
Pre-treatment of cells with thapsigargin, which inhibits cytosolic calcium influx 
from the endoplasmic reticulum, increased caspase-3 activity to a comparable extent as 
taxol, indicating that blocking of calcium signaling can induce apoptosis (Figure 4.7A,B). 
E2 or E2-BSA (Figure A4.5A) reversed this effect. Pertussis toxin (PTX), which inhibits 
Gαi signaling, also increased caspase-3 activity, as did cholera toxin (CTX), which 
inhibits Gαs signaling (Figure 4.7B). Neither E2 nor E2-BSA had an effect on PTX-
induced caspase-3 activity; however, both E2 and E2-BSA (Figure A4.5B) reduced the 
effect of CTX and taxol on caspase-3 activity, indicating that the anti-apoptotic effect of 




Figure 4.7: Role of Ca++ and G-protein Signaling in Apoptotic Signaling of E2 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2, while thapsigargin 
enhances caspase-3 activity alone and this is also reduced by E2. (B) Taxol-induced 
(20µM) caspase-3 activity is reduced by 10-8M E2, while pertussis toxin and cholera toxin 
both enhance caspase-3 activity alone. The effect of CTX is reduced by E2. Data is 
represented by the mean of 6 individual samples and error bars represent standard error 
of the mean. * represents p<0.05 compared to the untreated control group while # 
represents p<0.05 compared to 20µM taxol and $ represents p<0.05 compared to 
inhibitor alone. 
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4.3.9 Role of Palmitoylation 
HCC38 cells treated with 10-8M E2 for 9 minutes exhibited increased plasma 
membrane localization of ERα36, as determined by densitometry analysis of western 
blots (Figure A4.6A), while cells pre-treated for 2 hours with tunicamycin (Tm) or 2-
bromopalmitate (2-BP) did not (Figure 4.8A). Cycloheximide (CHM) had no effect on 
translocation of ERα36 to the membrane in response to E2 (data not shown), nor did it 
alter E2-dependent increases in PKC (Figure 4.8B) or PLD (Figure 4.8C). 2-
hydroxymyristic acid (HMA) reduced translocation of ERα36 (Figure 4.8A), but did not 
alter E2-dependent PKC or PLD. In contrast, Tm and 2-BP blocked ERα36 translocation 
and the stimulatory effects of E2 on PKC and PLD indicating that palmitoylation played a 
role in these effects. In addition, palmitoylation was required for the anti-apoptotic effect 
of E2. Tm blocked the effect of E2 on taxol-induced caspase-3 activity (Figure 4.8D) as 
did 2-BP (Figure 4.8E). Similar effects were observed in cells treated with E2-BSA 





Figure 4.8: Role of Palmitoylation in the Anti-apoptotic Effect of E2 
(A) Western blot of plasma membrane fractions of HCC38 cells treated with 10-8M E2 for 
9 minutes, pre-treated with 0.5mM HMA, 30µM Tm, or 10µM 2-BP for 2 hours indicates 
that ERα36 membrane-association occurs rapidly and is blocked by Tm and 2-BP. (B,C) 
Tm and 2-BP prevent the effect of 10-8M E2 on (B) PKC activation after 9 minutes and 
(C) PLD activation after 30 minutes. Data is represented by the mean of 6 individual 
samples and error bars represent standard error of the mean. * represents p<0.05 
compared to corresponding untreated control. (D,E) Taxol-induced (20µM) caspase-3 
activity is reduced by 10-8M E2, while (D) Tm (30µM) and (E) 2-BP (10µM) block this 
effect. Data is represented by the mean of 6 individual samples and error bars represent 
standard error of the mean. * represents p<0.05 compared to the untreated control 
group while # represents p<0.05 compared to 20µM taxol and $ represents p<0.05 






4.3.10 Proposed Mechanism by which E2 Blocks Taxol-induced Apoptosis in ER-
negative Breast Cancer 
Based on the results of this study, along with results from our previous work 
regarding E2’s non-genomic, membrane-mediated effects in HCC38 cells, we have 
developed a working model for the mechanism by which E2 promotes triple negative 
breast cancer cell survival, specifically through proliferative and anti-apoptotic effects. 
Interaction of E2 with ERα36 on the plasma membrane leads to a signaling cascade that 
begins with G-protein activation, specifically Gαs, leading to activation of 
phosphatidylcholine-specific PLD (Figure 4.9). PLD then converts phosphatidylcholine 
(PC) to phosphatidic acid (PA), which after conversion to lysophosphatidic acid (LPA) 
activates LPA receptors, which promote activation of PI3K. PI3K then promotes anti-
apoptotic activity, possibly through an Akt-dependent mechanism, which can prevent 
activation of a caspase signaling cascade that ultimately leads to caspase-3 activation 
and apoptosis. As taxol promotes caspase-3 activation through a mechanism detailed by 
Levin et al. (69), which includes JNK phosphorylation and cytochrome C release from 
the mitochondria, the mechanism of E2 inhibitory effect on caspase-3 activity counteracts 
the pro-apoptotic effect of taxol. At the same time, the activation of signaling through 
ERα36 can also promote PKC activation through PLC, diacylglycerol (DAG), and inositol 
trisphosphate (IP3). PLD can also further activate PKC, indicating cross talk between 
diverging pathways that are simultaneously activated by E2 at the plasma membrane. 
Overall, in the context of cancer cell physiology, we conclude that E2-membrane 
activation of ERα36 promotes proliferation, while simultaneously activating an anti-





Figure 4.9: Proposed Mechanism by which E2 Promotes Cancer Cell Survival 
E2 signaling through membrane-associated ERα36 activates two pathways, mediating 
the proliferative effect through a G-protein-PLC-PKC specific pathway and the anti-
apoptotic effect through PLD-LPA-PI3K specific pathway. Cross-talk can occur between 
these pathways as PLD can activate PKC via DAG and calcium-dependent PKC can 




Estrogen receptor (ER) status typically dictates classification, diagnosis, and 
treatment of breast cancer. ER-negative breast cancer, and particularly triple negative 
breast cancer (TNBC), must be treated with more rigorous means than ER-positive 
cancers, which traditionally respond more readily to anti-estrogens such as tamoxifen. 
Taxol is commonly used as an adjuvant chemotherapeutic drug in the treatment of 
several cancers including breast cancer (141-144). However, E2 is known to abrogate 
the effect of taxol (69), thereby promoting cancer cell survival through an anti-apoptotic 
mechanism. Therefore, a better understanding of the mechanism by which E2 promotes 
anti-apoptosis in breast cancer is necessary. 
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This study examined the mechanism by which E2 functions to promote breast 
cancer cell survivability. Our approach used antibodies, inhibitors, and activators of 
hypothesized proteins involved in the pathway. We used caspase-3 activity as our 
endpoint measurement, as we showed that caspase-3 is a downstream regulator of 
taxol-induced apoptosis and we previously showed that membrane-associated E2 
signaling abrogates the effect of taxol on caspase-3 activity (54). Taxol caused 
apoptosis in HCC38 cells in a similar manner to that seen in ER-positive MCF7 and ZR-
75-1 breast cancer cells through activation of Bcl2 associated proteins, cytochrome-C 
translocation, and caspase-3 activation (69). As we previously showed that membrane-
associated E2 signaling abrogated the effect of taxol in HCC38 cells (54), we wanted to 
elucidate the mechanism by which this occurs. 
HCC38 cells served as an in vitro model for TNBC. This cell line does not contain 
progesterone receptor (PR), Her2 receptor, or traditional ER. However, we have 
previously shown that HCC38 cells do express ERα36, an alternatively spliced variant of 
the traditional ERα (54). ERα36 was responsible for the membrane-mediated effect of E2 
that promotes rapid activation of PKC and proliferation. Membrane-associated E2 
signaling promoted anti-apoptosis against taxol-induced caspase-3 activity. However, at 
the time, we did not implicate ERα36 as the receptor responsible for this, although the 
results did suggest that ERα36 could be responsible for the activation of multiple 
membrane-associated pathways that promote cancer cell aggressiveness. The ability of 
antibodies against ERα36 and ERα36 silencing to prevent the anti-apoptotic effect of E2 
against taxol in this study proves that the anti-apoptotic effect is mediated specifically 
through membrane-associated ERα36. 
In this study, we have shown that ERα36 does in fact mediate the membrane-
associated anti-apoptotic effect of E2. Not only did our studies using antibodies against 
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ERα36 implicated it as the membrane receptor responsible for these effects, but 
membrane association is required for these effects, as is seen with the results using 
inhibitors to palmitoylation. Because we have determined that the anti-apoptotic effect of 
E2 is through a non-genomic, membrane-mediated mechanism that begins with 
E2/ERα36 interaction at the plasma membrane, we hypothesized that dynamic 
palmitoylation by palmitoylacetyltransferase (PAT), mediates the membrane effect of E2 
through ERα36 against taxol-induced caspase-3 activity. As we expected, due to several 
previous studies indicating membrane association of ERs, particularly ERα66 and 
ERα46 occurs due to palmitoylation of these receptors (39, 139), the membrane effect of 
E2 through ERα36 is mediated via palmitoylation and not myristolation. The use of 2-
hydroxymyristic acid, which prevents myristolation of proteins, did not abolish membrane 
association of ERα36. Our work using cycloheximide, HMA, tunicamycin, and 2-
bromohexadecanoic acid, indicates that membrane association of ERα36 can occur 
rapidly within ten minutes of treatment with E2, suggesting that E2 itself promotes rapid 
association of ERα36 with the plasma membrane via palmitoylation. Tunicamycin, a 
known inhibitor of palmitoylacetyltransferase, completely blocked the E2-induced 
membrane association of ERα36. However, tunicamycin is also known to be a potent 
inhibitor of N-glycosylation (39), indicating that it is not the most ideal inhibitory 
candidate for studying palmitoylation. The inability of cycloheximide to block the E2-
induced plasma membrane association of ERα36, cycloheximide a suitable control for 
this undesired effect of tunicamycin, as cycloheximide also inhibits N-glycosylation of 
proteins. 
To further support the role of palmitoylation of ERα36 in these anti-apoptotic 
membrane-associated effects of E2, we used 2-bromohexadecanoic acid, or 2-
bromopalmitate (2-BP) to specifically inhibit palmitoylacetyltransferase activity (140), 
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thereby preventing dynamic palmitoylation of ERα36. The effects of 2-BP were similar to 
those seen with tunicamycin, and with both inhibitors, we observed a reduction in rapid 
membrane association of ERα36, an inhibitory effect on E2-induced PKC and PLD 
activation, and complete abolishment of the anti-apoptotic effect of E2. Because 2-BP is 
a more specific inhibitor of PATs than tunicamycin, we concluded that the anti-apoptotic 
effect of E2 occurs with rapid and dynamic palmitoylation of ERα36 leading to membrane 
association of the receptor within minutes.  
In addition, ERα36 contains a unique C-terminal exon, exon 9, which codes for 
27 amino acids of unknown function. Wang et al. hypothesized that this exon contains a 
potential myristolation sequence (55). Therefore, we created ERα36 deletion mutants to 
determine if the anti-apoptotic membrane effect of E2 is dependent on the presence of 
exon 9. HEK293 cells were used a model for overexpression of wildtype exogenous 
ERα36 and exon 9-deleted ERα36 expression plasmids. Overexpression of ERα36 
lacking exon 9 suggested that this exon is required for the anti-apoptotic membrane 
effect of E2. We observed the requirement for exon 9 in the effect of E2 on PLD activity, 
but the role of exon 9 in the effect of E2 against taxol-induced caspase-3 was less clear. 
Because we observed an increase in caspase-3 activity when we removed exon 9 
without any other treatment, it is possible that the removal of exon 9 alters the overall 
effect of ligand-independent ERα36. Because our results indicate palmitoylation is the 
mechanism by which ERα36 translocates dynamically to the plasma membrane, and 
HMA did not prevent the effect of E2, further studies are necessary to determine if exon 9 
is a target for palmitoylation of ERα36.  
Previous results were not clear as to how E2 promotes anti-apoptosis (69). The 
vitamin-D3 metabolite, 24R,25-dihydroxyvitamin-D3, another steroid hormone which 
activates PKC through a similar mechanism as E2, has anti-apoptotic effects by 
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activating phospholipase D in chondrocytes (68). Based on this, we investigated whether 
E2 can rapidly activate PLD in breast cancer cells and found that E2 activated PC-PLD 
within 30 minutes, which occurred specifically through membrane-associated ERα36. 
Moreover, the ability of wortmannin to block the effect of E2 on taxol-induced caspase-3 
activity indicates that E2-specific PLD activity mediates the anti-apoptotic effect of E2 in 
breast cancer, and in this case, particularly in triple negative breast cancer cells.  
While PC-PLD was shown to play a role in the anti-apoptotic effect of E2, neither 
PI-PLC, nor PC-PLC appeared to be involved. Neither U73122 nor D609 abrogated the 
effect of E2; however, they both appeared to block the effect of taxol on caspase-3 
activity, suggesting a possible role of PLC in the mechanism by which taxol induces 
apoptosis. As Levin et al. showed that taxol induces apoptosis through a JNK-dependent 
mechanism (145), it is quite possible that JNK is activated through a pathway that 
requires PLC. Other studies show JNK activation can occur through a PKC-associated 
pathway. This may explain the effects seen on taxol-induced caspase-3 activity in the 
presence of D609 and U73122, which inhibit PC-PLC and PI-PLC respectively.   
The PI3K/Akt signaling pathway has been shown in several studies to be 
intimately associated with apoptotic and anti-apoptotic signaling in several cell types 
(146-149). Due to its well-known role in anti-apoptotic pathways, we hypothesized that 
PI3K is part of the pathway by which E2 exerts its anti-apoptotic effect. Although 
wortmannin is also known to inhibit PI3K, the concentration used in our study (10µM), 
can potently inhibit PLD, without measurable effects on PI3K activity (137). Not only did 
LY294002, a specific inhibitor of PI3K, block E2’s anti-apoptotic effect against taxol, but 
also the PI3K activator, 740 Y-P, alone prevented taxol's apoptotic effect in a similar 
manner to E2. Similarly, the addition of LPA, which is also known to regulate anti-
apoptosis through a PI3K-Akt-dependent mechanism (68), prevented the effect of taxol 
 81 
on cancer cell apoptosis. However, the use of the LPA signaling inhibitor, VPC32183S, 
which inhibits signaling of LPA via the LPA1 and LPA3 receptors (150), appeared to not 
only block the E2 anti-apoptotic effect, but also appeared to block taxol’s effect as well. 
Because this inhibitor is not specific to one isoform of the LPA receptor, it may have 
multiple competing effects on LPA signaling. These effects on taxol-induced apoptosis 
suggests that LPA signaling is a promiscuous process that may have differential effects 
on apoptotic signaling pathways, and although further investigation into the role of these 
receptors is necessary to achieve a definitive conclusion on which specific receptor is 
involved in the anti-apoptotic effect of E2, it may be that LPA signaling, while it appears 
to be a component of the anti-apoptotic effect of E2, may also function in the pathway by 
which taxol induces apoptosis. 
We originally hypothesized that G-protein and intracellular calcium signaling may 
also play a role in the anti-apoptotic effect of E2 against taxol-induced apoptosis. We 
used thapsigargin, an inhibitor of endoplasmic reticulum-associated calcium channels to 
block the influx of calcium to the cytosol. Interestingly, we observed a marked increase 
in caspase-3 activity when HCC38 cells were treated with thapsigargin alone. Although 
this effect was reduced by the use of E2, it was not clear whether calcium involvement in 
this anti-apoptotic effect of E2 was specifically through the pathway that includes PLD. 
Interestingly, as we have shown that PKC activity is important for the maintenance of 
cancer cell survival (54), these results suggest that PLC-specific PKC activation, which 
depends on calcium efflux from the endoplasmic reticulum, may not only promote cancer 
cell proliferation, but may also crosstalk with the anti-apoptotic pathway to block 
caspase-3 activation. Similarly, we also observed that pertussis toxin and cholera toxin, 
inhibitors of G-protein signaling through inhibition of Gαi and Gαs respectively, also 
showed marked increases in caspase-3 activity when used alone. Although we cannot 
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come to solid conclusions on the role of these G-protein subunits due to these results 
alone, it is interesting to note that the rapid activation of PKC in HCC38 breast cancer 
cells occurs via Gαs activation. We can also suggest that these effects of pertussis toxin 
and cholera toxin may be due to attenuation of LPA receptor signaling, which depends 
on G-protein function. It is important to note that the effect of pertussis toxin on caspase-
3 activity was not abrogated by E2. However, the effect of cholera toxin, which 
specifically inhibits Gαs signaling, was reduced with the addition of E2, and this result is 
consistent with the idea that PKC activation by E2 occurs by Gαs activation (57) and is 
anti-apoptotic. Although further investigation into the role of Gαs signaling in this 
pathway is necessary, the results suggest a membrane-delimited role of ERα36 in the 
anti-apoptotic pathway of E2. Either ERα36 directly activates Gαs, or another player may 
be involved.  
This study provides in-depth knowledge into the mechanism of membrane-
associated E2 signaling in triple negative HCC38 breast cancer cells producing a working 
model for E2 signaling through ERα36. The use of antibodies against ERα36, ERα36 
silencing, analysis of palmitoylation, and results with E2-BSA, which cannot cross the 
plasma membrane, prove that these effects of E2 are initiated at the plasma membrane. 
We previously showed that rapid activation of PKC is mediated by ERα36 at the plasma 
membrane and this effect leads to cancer cell proliferation. This study showed that the 
activation of ERα36 by E2 could also lead to activation of another pathway of anti-
apoptosis, which involves PC-PLD, LPA, and PI3K. Crosstalk can occur between these 
pathways due to the ability of PLD to activate PKC through a DAG-dependent 
mechanism, as well as PKC’s ability to promote anti-apoptosis as well. The elucidation 
of this signaling pathway permits a greater understanding of how E2 functions in breast 
cancer cells, particularly triple negative breast cancer cells, to block the effects of 
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chemotherapeutic drugs that target cancer cells for apoptosis. The role of ERα36 in this 
pathway, and the fact that we have shown that ERα36 mediates this effect from the 
plasma membrane, suggests that ERα36 may be a suitable target for diagnosis and 
treatment of breast cancer. Perhaps production of ERα36 specific monoclonal antibodies 
would provide another avenue to more robustly target and kill breast cancer cells 
overexpressing the receptor. In theory, targeting of ERα36 would prevent the anti-
apoptotic effect of E2 and thus provide a novel approach to personalized, adjuvant 
therapy against breast cancer. 
 
FINANCIAL DISCLOSURE 
 This work was supported in part by the Price Gilbert, Jr. Chair. It was also 
supported by the National Center for Advancing Translational Sciences of the National 
Institutes of Health under Award Number UL1TR000454 and TL1TR000456. The 
content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the 
manuscript. 
 84 
CHAPTER 5: 17beta-estradiol Promotes Aggressive Laryngeal Cancer through 




[Chapter 5 has been prepared for manuscript submission as: Chaudhri RA, Schwartz N, 
Hadadi A, Schwartz Z, Boyan BD. Estradiol Enhances Proliferation and Anti-apoptosis 




17β-estradiol (E2) plays a key role in tumorigenesis by enhancing cell 
survivability and metastasis through its cytoplasmic receptors. Recently, a variant of 
estrogen receptor alpha, ERα36 has been implicated as a substantial mediator of E2’s 
proliferative and anti-apoptotic effects through rapid membrane-associated signaling, 
and cancers previously regarded as hormone-independent due to the absence of 
traditional receptors, may in fact be susceptible to E2. Despite rising from a secondary 
sex organ and having a clear gender disposition, laryngeal cancer is not uniformly 
accepted as hormone-dependent, even in the face of compelling evidence of E2 
responsiveness. The aim of this study was to further elucidate the role of E2 in the 
tumorigenesis of laryngeal cancer, both in vitro and in vivo. ERα36 presence was 
evaluated in membranes of the laryngeal carcinoma cell line, Hep2, as well as in 
laryngeal tumor samples. In vitro, ERα36 was found to mediate rapid activation of 
protein kinase C and phospholipase D by E2, leading to increased proliferation and 
protection against chemotherapy-induced apoptosis. Furthermore, in response to E2 
activation of ERα36, an upregulation of angiogenic and metastatic factors was observed. 
Clinical analysis of laryngeal tumors revealed a similar association between the amount 
of ERα36 and VEGF, and indicated a role in lymph node metastasis. These findings 
present compelling evidence of ERα36-dependent E2 signaling in laryngeal cancer. 
Thus, targeting ERα36 may reduce the deleterious effects of E2 in laryngeal cancer, 
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ultimately suggesting the importance of anti-estrogen therapy or the production of novel 
drugs that specifically target ERα36. 
 
5.1 INTRODUCTION 
The mechanisms responsible for tumor growth and metastasis are complex and 
are only partially understood. One of the factors contributing to this process that has 
major clinical implications for both prognosis and treatment is the presence of hormone 
and growth factor receptors in cancer cells. 17β-estradiol (E2) traditionally acts as a sex 
hormone, involved in sexual development and the reproductive systems of males and 
females, but it has also many other effects both in non-reproductive tissues such as 
bone and in cancerous tissue. The importance of E2 in the pathogenesis of breast and 
prostate cancer is well established (70, 151). E2 is known to enhance cell proliferation, 
survivability, and metastasis (152-154). This deleterious effect of E2 is in fact the target 
of one of the main treatments in breast cancer, the anti-estrogen tamoxifen. 
Classically, the mechanism of E2 action is mediated through interaction with its 
cytoplasmic receptors, ERα and ERβ, which in turn act in the nucleus as transcription 
factors (155). There is increasing evidence that E2 acts via plasma membrane 
receptor(s), which rapidly activate signal transduction pathways, thus enhancing 
proliferation and attenuating apoptosis (31, 81). This membrane-mediated mechanism 
does not necessitate new gene expression or protein synthesis and is thought to be 
responsible for the E2 activation of protein kinase C (PKC) (57).  
One of the key candidates for the membrane mediated action of E2 is a novel 
ERα variant, with a molecular mass of ~36kDa (ERα36). It differs from the classical 
ERα66 by lacking both transcriptional activation domains (AF1/AF2), but retains the 
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DNA-binding domain as well as partial dimerization and an intact ligand-binding domain 
(53, 55). It also contains a novel C-terminal exon that encodes 27 amino acids of 
unknown function. We have previously shown that this alternative ER resides in the 
plasma membranes of breast cancer cells and mediates E2’s proliferative and anti-
apoptotic effects (54). 
Epidemiological studies have implied that sex hormones may be involved in the 
tumorigenesis of laryngeal carcinomas, due to the vast differences in gender 
susceptibility, with a male: female ratio of 11:1 (156). The larynx is a secondary sex 
organ, which undergoes trophic changes in response to hormonal changes during 
puberty, and morphostructural changes during adulthood. Nonetheless, while other 
tumors of secondary sex organs have been accepted as hormone dependent cancers, 
laryngeal carcinoma is still a subject of controversy, and as such, its treatment is not 
oriented to counteract the hormonal effect. 
The presence of classical cytosolic ERs is controversial in laryngeal cancer (157, 
158). Despite this, laryngeal cancer cells display E2 responsiveness, as E2 was found to 
increase proliferation of laryngeal cancer cells (159), and a non-genomic mechanism 
was implicated (160). Furthermore, the effects of E2 were inhibited by tamoxifen (161). 
These findings advocate a role for E2 in the tumorigenesis of laryngeal cancer and 
warrants further exploration of its effects. 
In order to further improve the understanding of the role of E2 in the 
tumorigenesis and metastasis of laryngeal cancer, we examined the underlying 
mechanism of E2’s effect in vitro using laryngeal cancer cell lines as the model. We 
hypothesized that the effect exerted by E2 on laryngeal cancer is similar to that found in 
breast cancer and that ERα36-associated E2 membrane signaling mediated by PKC is 
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involved in promoting proliferation, protecting against apoptosis and stimulating gene 
expression resulting in enhanced aggressiveness and metastasis of laryngeal cancer. In 
addition, we used immunohistochemistry to assess expression of ERa36 and vascular 
endothelial growth factor (VEGF) in histological samples from human laryngeal tumors in 
order to help clarify the role of E2 in vivo. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Reagents 
The Hep2 laryngeal carcinoma, TT thyroid carcinoma, HeLa cervical carcinoma, 
and HCC38 breast cancer cell lines were validated and obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). Minimum essential medium 
(MEM) and Roswell Park Memorial Institute (RPMI) 1640, both lacking phenol red were 
purchased from Invitrogen (Grand Island, NY, USA) and F12K nutrient mixture was 
purchased from Cellgro (Manassas, VA, USA). Charcoal/dextran-filtered fetal bovine 
serum (FBS) was purchased from Gemini Bioproducts (Sacramento, CA, USA). The 
estradiol enantiomer ent-17β-estradiol (Ent-E2) was kindly provided as a gift from 
Douglas Covey (Washington University, St. Louis, MO, USA) (125). E2, E2 conjugated to 
bovine serum albumin (E2-BSA), and taxol were purchased from Sigma (St. Louis, MO, 
USA). The PLD inhibitor wortmannin was purchased from EMD chemicals (Billerica, MA, 
USA). Protein content of samples was measured using the Macro BCA reagent kit from 
Pierce/Thermo Scientific (Rockford, IL, USA). Polyclonal ERα66 antibodies were 
purchased from Chi Scientific (Maynard, MA, USA), ERα36 antibodies were purchased 
from Cell Applications Inc. (San Diego, CA, USA), GAPDH antibodies were purchased 
from EMD-Millipore (Billerica, MA, USA), and caveolin-1 antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). VEGF antibodies were purchased 
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from Abcam (Cambridge, MA, USA). The PKC assay kit was purchased from GE 
Lifesciences (Pittsburgh, PA, USA). The Amplex Red Phospholipase D Assay kit was 
purchased from Life Technologies (Grand Island, NY, USA). The Titertacs TUNEL assay 
kit was purchased from R&D Systems (Minneapolis, MN, USA). The CaspAce assay kit 
was purchased from Promega (Madison, WI, USA). All primers were purchased from 
Eurofins (Huntsville, AL, USA). The IRB-approved larynx tissue microarray was 
purchased from Imgenex (San Diego, CA, USA). 
 
5.2.2 Cell Culture 
Hep2 and HeLa cells were cultured in MEM-based media, as specified by the 
ATCC, containing 10% charcoal/dextran-filtered FBS and lacking phenol red, which can 
mimic the effects of E2 at low levels. HCC38 cells were maintained in RPMI 1640-based 
media, while TT cells were cultured in F12K media. 
 
5.2.3 Presence of ER isoforms 
In order to determine whether laryngeal cancer cells express ERα36, sequence-
specific primers, designed in our lab previously (54), were used to selectively identify the 
traditional ERα66 and the alternatively spliced variant ERα36, as well as the E2 receptor, 
GPR30. RNA was extracted from Hep2, HeLa, HCC38, and TT thyroid medullary 
carcinoma cell lines cells using the TRIzol method. Reverse transcription was performed 
to produce cDNA for ERs from the laryngeal cell line. PCR was then performed to 
determine whether mRNAs for the receptors were expressed. Western blots of isolated 
membrane fractions were used to identify the subcellular localization of ERα66 and 
ERα36 in the cell lines. 
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5.2.4 PKC and PLD activity 
Subconfluent cultures of Hep2 cells were treated with E2, Ent-E2, and E2-BSA at 
the indicated time points and at a concentration of 10-8M unless otherwise specified. Ent-
E2 was used in order to determine if E2 response relies on a stereospecific receptor 
response. The use of E2-BSA, which cannot pass through the plasma membrane and 
reach the nuclear receptor (49, 132, 133), enables confirmation that the effects elicited 
by E2 are membrane mediated. The PLD inhibitor, wortmannin, was used at a 
concentration of 10-5M. ERα36 antibodies were used to block the effect of E2, in order to 
determine the role of ERα36 in the E2 activation of PKC and PLD. Wortmannin and 
ERα36 antibodies were used 15 minutes prior to E2 treatment. Cells were washed twice 
with phosphate buffer saline (PBS) and lysed in RIPA buffer at time of harvest. PKC 
activity was measured using the BioTrak PKC assay kit from GE Lifesciences. PLD 
activity was measured using the Amplex Red PLD assay from Life Technologies and 
normalized using the PicoGreen DNA quantification assay. ERα36 antibodies were used 
to block the effect of E2, in order to determine the role of ERα36 in the E2 activation of 
the PLD signal cascade.   
 
5.2.5 Cell proliferation, viability and apoptosis 
In order to establish whether signaling via ERα36 can protect against apoptosis, 
the Hep2 cell line was treated with taxol, a known chemotherapeutic agent that induces 
cell death, as previously demonstrated in breast cell lines (54). Subconfluent cultures 
were pretreated with E2 for 90 min followed by taxol treatment for 4 h, after which cells 
were assayed for caspase-3 activity, using the CaspAce assay kit from Promega 
(Madison, WI) and DNA fragmentation via TUNEL. Furthermore, cell proliferation was 
assessed as a function of DNA synthesis, using the Click-IT Edu assay from Invitrogen 
 90 
(Grand Island, NY). ERα36 antibodies were used to block the effect of E2, thus verifying 
the role of ERα36 in the E2 signal cascade.   
 
5.2.6 Expression of angiogenic and metastatic factors 
Quantitative RT-PCR was used to determine the effect of E2 on expression of 
vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2), which 
have been implicated in pathological angiogenesis associated with tumors (162-164). 
Snail1 and e-cadherin (CDH1), which are metastatic factors leading to epithelial to 
mesenchymal transitions (110) and the metastatic factor CXC chemokine receptor type 
4 (CXCR4) (165), were also measured in the Hep2 cell line. RT-PCR was performed 




A laryngeal cancer tissue microarray containing 39 histological slices of laryngeal 
cancer tissue was obtained from Imgenex Corp. Clinical information for the 39 patients 
with laryngeal carcinoma is presented in Table 5.1. Prior to immunohistochemistry, 
slides were placed in a 60°C oven for 30 minutes, deparaffinized, and rehydrated, and 
antigen presentation was achieved by heating in a pressure cooker for 3 minutes in 0.1M 
sodium citrate buffer. ERα36 and VEGF presence was examined by 
immunohistochemistry using the LSAB immunohistological staining kit from Santa Cruz 





Table 5.1: Larynx TMA characteristics. 
A total of 39 laryngeal cancer subject tissues were examined by immunohistochemistry 
and blindly scored by 3 independent observers. The characteristics in the table above 
describe the age, sex, tissue type, TNM classification, and staging characteristics for 
these 39 subjects. 
Table 5.1: Laryngeal Cancer Patient Characteristics (N=39) 
Age   
Mean(SD) 60(8.68) 
> 50  36  
≤ 50  3  
Sex   
Male 38 
Female 1 




Pyriform Sinus 5 
Subglottic 5 
TNM  Classification 0  1  2 3 4 
Tumor Size  0 1 1 16 21 
 Lymph Node Metastasis 16 4 17 1 N/A 
Metastasis  38  1 N/A N/A N/A 
Stage I II III IV( A, B, C) 




5.2.8 Imaging and scoring 
Slides were imaged using a Leica DMLB microscope system with a 63X objective 
oil immersion lens. Images were taken with ImagePro for all samples and blindly scored 
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by three independent observers according to the scoring method listed in Table 5.2. 
ERα36 presence in all tissues was scored according to two classifications: ERα36 
number describes the number of cells in the tissue that are positive for ERα36; ERα36 
intensity describes the intensity of the staining, which describes cells that express either 
low amounts of ERα36 or high amounts of ERα36. VEGF was scored in a similar 
manner to ERα36 for VEGF number and VEGF intensity. 
 
 
Table 5.2: Histology Scoring Method 
All samples were scored blindly by three independent observers. Scores were then 
compared and for samples that were not scored the same by all three observers, the two 
most common scores were used. If no scores matched, a fourth observer blindly 
determined the score. 
Table 5.2: Immunohistological Scoring Method 
 Score Representation 
ERα36 Number 0 <1% cells positive 
 1 1<10% cells positive 
 2 10<50% cells positive 
 3 ≥50% cells positive 
ERα36 Location 0 Nuclear 
 1 Non-nuclear 
ERα36 Intensity 0 Low 
 1 High 
VEGF Number 0 <1% cells positive 
 1 1<10% cells positive 
 2 10<50% cells positive 
 3 ≥50% cells positive 
VEGF Intensity 0 Low 
 1 High 
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5.2.9 Statistical analyses 
For all in vitro experiments, data is represented as the mean and standard error 
among 6 individual samples. Statistical analyses were performed by analysis of variance 
with Bonferroni’s correction for Student’s t-test at a significance level of α≤0.05. 
Histological samples were scored blindly by three independent observers, and 
correlations of ERα36 number and intensity to clinicopathological variables were 
performed using Fisher’s exact test. 
 
5.3 RESULTS 
RT-PCR results showed that Hep2 laryngeal carcinoma epithelial cells expressed 
the alternative splicing variant to the traditional ERα, ERα36 (Figure 1A). The cells also 
expressed mRNA for the classical ERα66, as well as the non-classical G-protein coupled 
estrogen receptor GPR30 (Figure 5.1A). The presence of ERα36 protein was confirmed 
by western blot analysis, which demonstrated that Hep2 cells contained protein for 
ERα36. While ERα36 was also identified in the TT thyroid cancer cell line, it was more 
pronounced in the Hep2 laryngeal cells (Figure 5.1B). Plasma membrane isolation of 
Hep2 cells and western blot analysis showed that ERα36 was present in Hep2 plasma 
membranes along with caveolin-1, a protein found in the caveolae, which are specifically 
invaginated compartments of the plasma membrane that are known to house many 
integral membrane receptors (Figure 5.1C); however, TT cells did not appear to have 
detectable levels of plasma membrane-associated ERα36, although caveolin-1 was 
found in this fraction (Figure 5.1D). HCC38 breast cancer cells and HeLa cervical cancer 
cells were used as positive controls for ERα36 presence in the plasma membrane 
(Figure 5.1C,D). This is in agreement with our previous results, which placed this 
receptor in the plasma membrane of different cell lines (54). 
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Figure 5.1: Presence of ERs in laryngeal and thyroid cell lines 
RT-PCR shows that both the TT thyroid medullary and Hep2 laryngeal carcinoma cell 
lines express both the traditional ER, ERα66, and the novel variant, ERα36, as well as 
the non-traditional G-protein coupled ER, GPR30 (A). Western blots of whole cell lysates 
from both the TT and Hep2 cell lines show that they both contain protein for the novel 
receptor, ERα36, but it appears at least qualitatively, that the Hep2 cell line contains 
more (B). Western blots on plasma membrane fractions show the presence of ERα36 in 
the plasma membranes of Hep2 cells, but not in TT cells(C, D). 
 
 
E2 caused a significant increase in PKC activity after 30 minutes of treatment 
(Figure 5.2A). The effect of E2 was biphasic, with a significant increase in PKC at 10-9M 
and 10-8M but with no effect at 10-7M E2 (Figure 5.2B). E2’s effect was abolished with the 
specific PLD inhibitor wortmannin (Figure 5.2C) or by antibodies specifically against 
ERα36 (Figure 5.2D). Furthermore, E2 stimulated PLD activity. This effect appeared after 
60 minutes (Figure 5.3A), between the concentrations 5X10-9-10-8M E2 (Figure 5.3B). 
The enantiomer of E2 (Ent-E2) had no effect on PLD activity (Figure 5.3C). In addition, 
E2-BSA had a stimulatory effect at a concentration of 10-9M on PLD activity in the Hep2 
cells (Figure 5.3D). Using antibodies specifically against ERα36 to block the receptor 
prior to E2 treatment abolished the effect of E2 on PLD activity (Figure 5.3E). 
 95 
 
Figure 5.2: Estradiol effects on PKC activity in Hep2 laryngeal carcinoma cells 
A time course evaluation of PKC activity in response to 10-8M E2 treatment of Hep2 cells 
shows that PKC activity is enhanced 30 minutes after treatment (A), while in response to 
different doses of E2, a biphasic effect is observed (B). Pre-treatment for 15 minutes with 
10-5M wortmannin and 1:500 ERα36 antibody, prevent the effect of E2 on PKC (Figures 




Figure 5.3: Estradiol effect on PLD activity in Hep2 laryngeal carcinoma cells 
A time course evaluation of PLD activity in response to 10-8M E2 treatment of Hep2 cells 
shows that PLD activity is enhanced 60 minutes after treatment(A), while a biphasic 
effect is observed in response to different doses(B). When the enantiomer for E2, Ent-E2, 
is used to treat Hep2 cells, no increase in PLD activity is observed(C). When E2-BSA is 
used to treat Hep2 cells, an increase in PLD activity is only observed with 10-9M E2-
BSA(D). When Hep2 cells were pre-treated with antibody against ERα36, the effect of E2 
on PLD activity was abolished(E). *p<0.05 vs. corresponding control; #p<0.05 compared 
to E2 only. 
 
 
In order to determine the physiological effects of E2 signaling mediated by 
ERα36, we further examined cell survivability and downstream gene expression related 
to angiogenesis and metastasis. Initially, taxol was used to induce apoptosis, in order to 
assess the anti-apoptotic effects of E2 in cancer cells. The TUNEL assay, which 
measures DNA nicks associated with apoptosis, showed that taxol enhanced TUNEL, 
while pre-treatment with 10-8 and 10-7M E2 prevented this effect (Figure 5.4A). While 
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taxol additionally enhanced caspase-3 activity, an enzyme that plays a major role in 
apoptosis, 10-8M E2 also blocked this effect (Figure 5.4B). . E2 also exhibited a 
proliferative effect in Hep2 cells, as evident from the enhanced DNA synthesis (Figure 
5.4C). Pre-treatment of Hep2 cells with ERα36 antibodies (1:500 dilution) blocked these 




Figure 5.4: Role of E2 in Hep2 laryngeal carcinoma cell survival 
Taxol increased TUNEL and this was blocked by 10-8-10-7M E2(A). 10-8M E2 also 
inhibited the ability of taxol to increase caspase-3 activity, while antibodies against 
ERα36 reduced this effect of E2(B). 10-8-10-7M E2 increased cell proliferation, but in the 
presence of ERα36 antibodies, this effect was not evident(C). *p<0.05 vs. corresponding 
control; #p<0.05 compared to taxol only; $p<0.05 compared to anti-ERα36 only. 
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Quantitative RT-PCR analysis showed that 10-8M E2 increased mRNA levels of 
the angiogenic factors VEGF (Figure 5.5A) and FGF2 (Figure 5.5B), while ERα36 
antibodies (1:500 dilution) blocked this effect. The migratory factor CXCR4 (Figure 5.5C) 
showed a similar enhancement with E2 treatment and this was again blocked with 
ERα36 antibodies. Furthermore, E2 enhanced the metastatic factor Snail1 (Figure 5.5D), 
while down-regulating the expression of e-cadherin (CDH1) (Figure 5.5E), and both of 
these effects by E2 were blocked by ERα36 antibodies. mRNA levels were all normalized 






Figure 5.5: Role of ERα36 in E2’s effect angiogenic and metastatic factor 
expression 
10-8M E2 increased mRNA levels of pro-angiogenic factors VEGF(A) and FGF2(B), and 
the metastatic factors CXCR4(C) and Snail1(D), while antibodies to ERα36 blocked this 
effect. The effects on Snail1 were accompanied by a corresponding decrease in E-
Cadherin (CDH1) mRNA levels that was also inhibited by ERα36 antibodies(E). All 
values were normalized to GAPDH mRNA levels. *p<0.05 vs. corresponding control; 
#p<0.05 vs. E2 only. 
 
 
The blinded analysis of laryngeal cancer immunohistochemical staining for 
ERα36 demonstrated that all laryngeal cancer patient tissues were positive for the 
presence of the membrane receptor. There was a variance in the distribution of the 
receptor and in the degree of positive staining for the receptor. Tissues containing less 
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ERα36 also appeared to contain less VEGF, and vice versa (Figure 5.6). Samples with 
relatively low ERα36 appeared to also contain less VEGF (Figure 5.6A). Conversely, 
samples that exhibited strong punctate staining of ERα36 also had punctate staining of 
VEGF, which appeared to occur around blood vessels (Figure 5.6B). While some 
samples with relatively high ERα36 exhibited moderate amounts of VEGF (Figure 5.6C), 
others appeared to stain strongly for VEGF (Figure 5.6D). Amongst the study sample, all 
samples exhibited positive staining for ERα36 and VEGF, and a correlation was found 
between the number of ERα36 receptors and the number of VEGF (p=0.0178) (Table 
5.3). ERα36 number and intensity was further found to correlate with metastasis to 
regional lymph nodes (p=0.0263 and p=0.0119, respectively). However, we did not 
observe a correlation between ERα36 number and intensity with other variables such as 




Figure 5.6: Larynx TMA ERα36 and VEGF Immunohistochemistry 
Sample with low ERα36 and low VEGF levels(A). Samples with strong punctate staining 
of ERα36 accompanied by strong punctate staining of VEGF in blood vessels(B). 
Sample with high levels of ERα36, and moderate amounts of VEGF(C). Sample with 
strong ERα36 and VEGF staining(D). 
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Table 5.3: Larynx TMA statistics 
Table 5.3: Larynx TMA Statistics 
Association of: With: Significant? P-value 
ERα36 Number Age (≤50 vs. >50) no 0.6057 
 Tumor size by TNM staging no 0.6057 
 Metastasis to regional lymph nodes yes 0.0263 
 VEGF intensity no 0.2156 
 VEGF number yes 0.0178 
 ERα36 Intensity Age (<50 vs. >50) no 0.4520 
 Tumor size by TNM staging no 0.3698 
 Metastasis to regional lymph nodes yes 0.0119 
 VEGF number no 0.7250 




E2 has been studied in multiple ER expressing cells as a potential factor that 
influences tumorigenesis. In breast cancer, the prototype of ER expressing cancer cells, 
ER-negative tumors have been found to respond to E2 with increases in PKC activity, 
which correlates with enhanced tumorigenicity (54). The discovery of a novel ER variant, 
ERα36, opened the possibility that cancers previously labeled as non-hormone 
dependent and ER negative might in fact be susceptible to the effects of E2 via this 
membrane receptor, as was demonstrated in ER negative breast cancers (54, 57). In 
breast cancer, ERα36 was found to be a key cellular and transcriptional regulator of 
proliferation and enhanced aggressiveness (54, 55), thus emphasizing the importance of 
characterizing further its presence and role in other cancers that are subject to the 
influences of sex hormones.  
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Previous work has suggested that laryngeal squamous cell carcinomas exhibit 
sex-hormone dependent behavior (158). Here we show that laryngeal carcinoma cell 
lines possess functional ERα36 and it is present in the plasma membranes. The 
existence of ERα36 in the plasma membrane was not uniform in all cancer cells, 
however, as demonstrated by the lack of ERa36 in TT thyroid cancer cells.  
Previous studies in breast cancer demonstrated that ERα36 is localized 
specifically in the caveolae and is responsible for the E2 activation of the PKC signaling 
cascade (54). This was also the case for Hep2 cells; ERa36 was localized with caveolin-
1, indicating its present in caveolae. Moreover, E2 stimulated PKC activity in Hep2 cells 
via a mechanism comparable to that seen in the breast cancer cells. E2 caused an 
increase in PKC activity that was d36ependent on PLD, based on its inhibition by 
wortmannin. E2 activated PLD via a receptor mediated mechanism; the enantiomer of E2 
had no effect and antibodies to ERa36 blocked E2-dependent increases in PLD activity. 
It was also membrane-dependent as E2-BSA was able to elicit the response. 
Furthermore, blocking ERα36 signaling with antibodies abolished the protective and 
proliferative effects of E2, indicating that ERα36 has a role in tumorigenesis of laryngeal 
cancer and in the anti-apoptotic effect of E2 against chemotherapeutics. 
PKC has a key role in promoting tumorigenesis (166). Higher PKC activity 
correlates in vivo to enhanced tumor aggressiveness and progression (54, 103, 166), 
while in vitro, activation of the PKC signaling pathway enhances cell proliferation and 
survival via an anti-apoptotic mechanism (54, 57). Activation of PKC initiates a signaling 
cascade that results in activation of the ERK1/2 family of mitogen activated protein 
kinases (MAPK), providing an alternative method for steroid hormones to modulate gene 
expression rather than by traditional nuclear receptor mediated pathways (54).  
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PKC expression in laryngeal cancer was reported to be significantly higher than 
that found in normal laryngeal epithelium and adjacent non-cancerous 
laryngeal epithelium and was correlated with clinical stage and cervical lymph node 
metastasis (167). In our study, in response to E2, Hep2 cells demonstrated an increase 
in PKC activity followed by an upregulation of angiogenic and metastatic factors. Clinical 
analysis of patients with laryngeal cancer revealed an association between the number 
and concentration of ERα36 and metastasis to regional lymph nodes. A similar 
relationship was observed in other cancer cells, such as breast (54) and gastric 
carcinoma (108). Previous studies found that E2 activation of PKC mediates the 
expression of several metastatic factors such as Snail1 and Snail2, which down-regulate 
the cell-cell interaction proteins such as cadherins, leading to what is known as an 
epithelial to mesenchymal transition (105), thus promoting tumor metastasis (54). 
Tamoxifen was found to exert its effect, among others, by inhibiting the PKC signal 
pathway (57, 168), thus opening the possibility that tamoxifen may be considered in the 
treatment of laryngeal cancer.    
There are a number of alternative mechanisms by which PKC is activated and 
regulated via a membrane receptor, of which phospholipase A2, phospholipase C and 
phospholipase D have a prominent role. The mechanism by which this family of 
phospholipases cleaves different membrane phospholipids, such as phosphatidylcholine 
or phosphatidylinositol, to form diacylglycerol (DAG), thus activating PKC is well studied 
(68). However, there is increasing evidence that this mechanism isn’t one directional, as 
in the case of PLD, in which PKC was found to be an upstream regulator of PLD (167). 
Moreover, PLD in itself has anti-apoptotic effects, through the production of 
lysophosphatidic acid, which in turn leads to decreased caspase-3 activity (68). Our 
findings support that in laryngeal cancer, E2 exerts its effects through the PLD-PKC 
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pathway. Further research is needed in order to elucidate the mechanism by which this 
pathway renders laryngeal cancer cells sensitive to the effects of E2. 
These effects can explain the ability of E2 to enhance tumor aggressiveness 
directly by allowing cells to proliferate and evade the effects of common 
chemotherapeutics. Not only can these cells proliferate and evade apoptosis in the 
presence of E2, but E2 may also lead to a more aggressive cancer by leading the primary 
tumor and metastasizing to other secondary sites in the patient. As tumors grow, cells 
within the tumor secrete VEGF, leading to vascularization of the tumor and providing a 
network through which these tumor cells can enter the vasculature and travel throughout 
the body. Our previous results showed that E2 enhanced VEGF and FGF expression in 
vitro and the in vivo correlation between ERα36 and VEGF suggest that patients with 
high levels of ERα36 may have a more aggressive tumor phenotype as evidenced by the 
correlation to lymph node metastasis. These patients may benefit from treatments such 
as tamoxifen, which can block signaling of E2 through ERα36, regardless of whether 
they contain traditional ERs. 
As opposed to breast cancer in which the role of E2 signaling has been studied 
mainly in female patients, in this study we observed that E2 plays also a major role in 
development of cancer in male patients. Our findings suggest that male patients with 
laryngeal cancer, and possibly other cancers that are hormone-dependent, may benefit 
from ER-targeting treatments. Originally we sought to determine if the role of ERα36 in 
laryngeal cancer is sex-dependent, but were unable to do so due to the low frequency of 
laryngeal cancer in women and thus our sample of tissues contained samples from 
mostly male patients.  
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The findings of this study present compelling evidence that laryngeal cancer is 
hormone responsive, specifically to the effects of E2, via ERα36. This membrane 
receptor activates several pathways, which were found, both in vitro and in vivo, to 
correlate with laryngeal cancer progression and aggressiveness. E2 also elicits anti-
apoptotic effects that can oppose the effects of chemotherapeutic agents, such as taxol, 
and might thus confer resistance to treatment. Further investigation is warranted in order 
to elucidate the role of E2 and this membrane-mediated mechanism and to shed light on 
its impact on the treatment and management of laryngeal cancer clinically. 
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CHAPTER 6: Association of Estrogen Receptor-Alpha 36 and Vascular Endothelial 




[Chapter 6 has been prepared for manuscript submission as: Chaudhri RA, Hadadi A, 
Lobacheva A, O’Regan RM, Schwartz Z, Boyan BD. ERα36 in Human Breast Cancer 




Estrogen receptor alpha 36 (ERα36), an alternatively spliced variant of traditional 
ERα, has been shown to play a major role in non-traditional estrogen signaling, 
especially in ER-negative and triple negative breast cancer (TNBC) cells. ERα36 
mediates effects of 17b-estradiol (E2) by promoting cancer cell proliferation, anti-
apoptosis, and production of local growth factors. The aim of this study was to 
investigate the association of ERα36 with clinical variables such as patient age, tumor 
size, metastasis, and stage, levels of vascular endothelial growth factor (VEGF), and 
patient survival. Immunohistochemistry for ERα36 and VEGF was performed on a breast 
cancer tissue microarray (TMA) consisting of a 40-subject cohort. Slides were imaged 
and blindly scored by three independent observers assessing the number of 
immunopositive cells, location, and intensity of the stain. Univariate and multivariate 
statistical analyses were performed to determine the relation of ERα36 and VEGF with 
clinical variables. Survival analyses were also performed. Our results show an 
association of age and VEGF intensity with ERα36 intensity. These results, in 
combination with in vitro results showing that ERα36 can mediate the effect of E2 on 
mRNA levels of angiogenic and metastatic factors, suggest that ERα36 signaling in 
breast tumors can promote tumor vascularization leading to tumor progression and poor 
clinical outcome. In addition, survival analysis showed that even though only human 
epidermal growth factor receptor 2 (HER2), stage, and node metastasis showed a 
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predictive value of survival in the overall cohort, a subset of patients with high amounts 
of ERα36 additionally showed that progesterone receptor (PR) status, VEGF intensity, 
and tumor size also showed significant effect on survival. This study shows that ERα36 
presence is significantly correlated to several clinicopathological factors in breast cancer 
tissue and may have an effect on survival. These data suggest that therapeutic 
intervention targeting ERα36 can potentially reduce tumor growth, angiogenesis, and 
metastasis, and may provide a survival benefit for patients overexpressing ERα36.   
 
6.1 INTRODUCTION 
Breast cancer is a heterogeneous disease of which several risk factors may 
predict outcome depending on specific patient characteristics (5, 169). The presence of 
estrogen receptors (ERs) is one major method of classifying patients and may determine 
treatment regimens (170). Typically, ER-positive tumors are hormone-dependent, 
growing in the presence of estrogen, and therefore, many adjuvant treatments aim to 
counteract the effects of estrogen. Tamoxifen, the most common anti-estrogen used in 
the treatment of breast cancer, is typically prescribed as an adjuvant treatment in 
conjunction with either surgery or radiotherapy, and in patients post-operatively, it is 
recommended to be prescribed for 5 years following tumor removal (171). ER-negative 
tumors, however, are typically thought of as non-responsive to anti-estrogens, and 
therefore, treatment is much more difficult in these patients (58). Furthermore, triple 
negative breast cancer (TNBC) patients tend to be the most difficult patients to treat as 
they not only lack ERs, but also progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) (58). Both PR and HER2 play roles in tumor 
development and may be targeted for treatment, but in patients lacking all three 
receptors treatment options after surgery and radiotherapy are limited to standard 
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chemotherapy rather than targeted chemotherapy, leading to adverse side effects in 
patients as standard chemotherapeutics exhibit cytotoxic effects that do not tend to 
differentiate normal cells from cancer cells.  
The identification of novel targets for treatment is crucial in the fight against 
breast cancer, especially in breast cancer patients who have limited options for 
treatment. ERα36, an alternatively spliced variant of traditional ERα, or ERα66, has been 
shown by several in vitro studies to play a major role in non-traditional estrogen signaling 
in breast cancer cells, especially in ER-negative or TNBC cells (54, 59, 82, 108, 172). 
The consequences of this non-traditional signaling are widespread, but most importantly, 
ERα36 can mediate effects of 17b-estradiol (E2) that promote cancer cell proliferation, 
anti-apoptosis, and production of local factors (54). These local factors include growth 
factors that promote angiogenesis, epithelial to mesenchymal transition (EMT), and cell 
migration. Therefore, we wanted to investigate the association of ERα36 with variables 
such as patient age, tumor size, metastasis, stage, and levels of vascular endothelial 
growth factor (VEGF). We used a commercially available breast cancer tissue 
microarray (TMA), which allowed us to perform consistent immunohistochemistry for 
ERα36 and VEGF in all subject samples of the cohort. The TMA permits direct 
comparison of every sample in the cohort without experimental bias that normally could 
be found in immunohistochemistry (IHC) experiments using a large amount of samples 
on individual slides. We also determined the role of ERα36 and VEGF, as well as 
several clinical variables, with 5-year survival. 
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6.2 MATERIALS AND METHODS 
 
6.2.1 Breast Tissue Microarray 
The Institutional Review Board-approved breast tissue microarray (TMA) used in 
this study was purchased from Imgenex (San Diego, CA). Slides provided contained 
fifty-nine samples that were represented by forty different patient cases. The TMA also 
included samples from 10 of the subjects in the original cohort of 40 that were from 
metastatic tissue from lymph nodes. Nine additional samples from matched adjacent 
normal tissue were also included. 
Characteristics of the patient cohort used in this study can be seen in Table 6.1. 
The mean age was 47(SD=8), but for this study, age was divided into patients under the 
age of 50 and patients 50 and older. As we were unable to obtain information on 
menopausal status, and although this is not directly representative of patient 
menopausal status, we made the general assumption based on published statistics that 
the vast majority of women over the age of 50 are post-menopausal, whereas women 
under the age of 50 are typically pre-menopausal (173). The other variables we 
analyzed in this study included TNM variables, p53 status, receptor status, and 
histological stage. TNM, which describes tumor growth and spread, is broken down into 
three variables: T describes the tumor size or extent and is scored from T0 to T4, with 
T0 being no observable tumor and T1-4 representing increasing growth and spread of 
the tumor; N describes spread of the cancer from the primary site to regional lymph 
nodes, with N0 indicating no observable metastasis to regional lymph nodes, and N1-3 
describing extent of spread from proximal lymph nodes to more distant lymph nodes; M 
indicates the presence of distant metastases, with M0 indicating no distant metastasis 
and M1 indicating metastasis has occurred beyond regional lymph nodes. In this cohort, 
we only observed patients whom were classified as either T2 or T3, and therefore, all 
 110 
analyses concerning this characteristic excluded T0, T1, or T4. Lymph node metastasis 
was observed in 65% of the subjects, while 14 subjects were classified as having no 
evident lymph node metastases (N0). ER status and PR status were both observed as 
being divided 70% to 30%, negative and positive, respectively, while HER2 status was 
observed 77.5% to 22.5%. Histological stage was observed as 30% of the subjects 
classified as IIA, 30% as IIB, 22.5% IIIA, and 17.5% IIIB. In this study, we analyzed the 
difference in associations between stage II and stage III subjects as survival drastically 
reduce from stage II to stage III (174, 175). 
 
 





The sections were paraffin-embedded onto a single slide containing all fifty-nine 
samples. This allowed for consistent immunohistochemical staining among all samples, 
thereby permitting direct comparisons among samples. Prior to immunohistochemistry, 
slides were deparaffinized by heating in a 60°C oven for 30 minutes, followed by 
washing three times in xylene for 1 minute each wash, two times in 100% ethanol for 1 
minute each, two times in 95% ethanol for 1 minute each, and tap water for 5 minutes. In 
order to unmask antigens, slides were heated in a pressure cooker for 3 minutes 
immersed in 10mM sodium citrate buffer (pH 6.0). After removal from the pressure 
cooker, slides were placed in room temperature sodium citrate buffer to cool for 20 
minutes, after which time they were washed in tap water three times for 2 minutes each 
wash. 
After antigen retrieval, immunohistochemistry was performed using the using the 
Immunocruz™ rabbit LSAB staining system from Santa Cruz Biotechnology (Santa 
Cruz, CA). In order to quench endogenous peroxidase activity, slides were incubated for 
5 minutes in hydrogen peroxide solution, rinsed with 1X phosphate-buffered saline 
(PBS), and washed for 2 minutes in 1X PBS at room temperature. Slides were then 
blocked with 5% normal goat serum for 20 minutes. Anti-ERα36 specific antibodies were 
purchased from Cell Applications, Inc. (San Diego, CA). Anti-VEGF antibodies were 
purchased from Abcam (Cambridge, MA). Anti-ERα36 and anti-VEGF antibodies were 
then applied to the slides at a 1:50 dilution. After 2 hours, the slides were washed two 
times with 1X PBS for 2 minutes each. Slides were then incubated for 30 minutes with 
biotinylated secondary antibody and washed twice again with 1X PBS for 2 minutes 
each wash. After secondary antibody incubation, slides were incubated for 30 minutes 
with horseradish peroxidase (HRP)-streptavidin solution followed by two washes with 1X 
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PBS for 2 minutes each. After the HRP-streptavidin incubation, slides were then 
incubated for 10 minutes with diaminobenzoate (DAB) chromogen and peroxide, which 
was prepared following the manufacturer’s instructions. Following this incubation, slides 
were washed two times with deionized H2O for 2 minutes each and then counterstained 
with Gill’s haematoxylin for 10 seconds. Slides were immediately washed with tap water 
until all excess haematoxylin cleared and then were destained with acid alcohol and 
bluing reagent, followed by another wash with tap water. Slides were finally dehydrated 
twice with 95% ethanol for 10 seconds each, twice with 100% ethanol for 10 seconds 
each, and three times in xylene for 10 seconds each. Excess xylene was removed from 
the slides and slides were finished with Cytoseal mounting medium (ThermoFisher 
Scientific, Waltham, MA) and coverslipped. 
 
6.2.3 Imaging and scoring 
Slides were imaged using a Leica DMLB microscope system with a 63X objective 
oil immersion lens. Images were taken with ImagePro for all samples and blindly scored 
by three independent observers according to the scoring method listed in Table 6.2. 
ERα36 presence in all tissues was scored according to three classifications: ERα36 
number describes the number of cells in the tissue that are positive for ERα36. ERα36 
location describes whether the majority of positive cells express ERα36 primarily in the 
nucleus or if ERα36 is present throughout the cells, indicating cytosolic and membrane 
presence. ERα36 intensity describes the intensity of the staining, which describes cells 
that express either low amounts of ERα36 or high amounts of ERα36. VEGF was scored 
in a similar manner to ERα36; however, no score for VEGF location was included as all 
VEGF is a secreted growth factor. 
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Originally, we wanted to determine the role of ERα36 by comparing patient 
tissues positive for ERα36 to patient tissues negative for ERα36. The fact that all 
samples contained ERα36 prevented us from answering our original question; however, 
we did perform the analysis comparing patient tissues showing more than 50% of cells 
positive for ERα36 (ERα36 number score of 3) to patient tissues showing less than 50% 
of cells positive for ERα36 (ERα36 number score of 2). 
 
 
Table 6.2: Histology Scoring Method 
All samples were scored blindly by three independent observers. Scores were then 
compared and for samples that were not scored the same by all three observers, the two 
most common scores were used. If no scores matched, a fourth observer blindly 




6.2.4 Statistical analysis 
All statistical analyses were performed in SAS. The PROC FREQ procedure was 
used to analyze comparisons of variables using Fisher’s exact test. Fisher’s exact test is 
a more accurate measurement of comparison than the Chi-square test because it gives 
 114 
an exact p-value rather than an approximation, and it is especially useful in analyses 
where sample size is a concern. Survival analyses were performed using the PROC 
LIFETEST procedure, which was also used to produce survival curves. Patients with 
final follow up times prior to 5 years who were not deceased were censored at the time 
that they last attended follow-up. All predictors of survival were determined by the Log-
Rank test for differences in survival.  
 
6.3 RESULTS 
 The blinded analysis of immunohistochemical staining for ERα36 demonstrated 
that all breast cancer patient tissues were positive for the presence of the membrane 
receptor. Figure 6.1 shows 3 representative samples stained for the presence of ERα36 
and VEGF by immunohistochemistry. Figure 6.1A shows the majority of cells in the 
tissue are positive for ERα36 and the location is primarily nuclear. The corresponding 
VEGF staining was scored as 1 for VEGF number, indicating greater than 1% and less 
than 10% of cells positive for VEGF, and 0 for VEGF intensity, indicating low intensity. 
Figure 6.1B shows a sample in which less than 50% of the cells are positive for ERα36 
and the presence in the positive cells is dispersed throughout the cells. This sample was 
also scored as low for ERα36 intensity, according to all observers. The corresponding 
VEGF staining was scored as 3 for VEGF number, indicating greater than 50% of cells 
positive for VEGF, and 0 for VEGF intensity, indicating low intensity. Figure 6.1C shows 
a sample with an ERα36 number score of 3, indicating greater than 50% positive cells, 
an ERα36 location score of 1, indicating presence throughout the cells, and an ERα36 
intensity score of 1, indicating high intensity. The corresponding VEGF staining was 
scored as 3 for VEGF number, indicating greater than 50% of cells positive for VEGF, 
and 1 for VEGF intensity, indicating high intensity. 
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Figure 6.1: ERα36 and VEGF Immunohistochemistry in breast TMA samples. 
(A) Sample with high ERα36 number (score=3), nuclear ERα36 location (score=0), low 
ERα36 intensity (score=0), low VEGF number (score=1), and low VEGF intensity 
(score=0). (B) Sample with moderate ERα36 number (score=2), cytosolic ERα36 
location (score=1), low ERα36 intensity (score=0), moderate VEGF number (score=2), 
and low VEGF intensity (score=0). (B) Sample with high ERα36 number (score=3), 
cytosolic ERα36 location (score=1), high ERα36 intensity (score=1), high VEGF number 
(score=3), and high VEGF intensity (score=1). 
 
 
Scoring results for breast cancer samples can be seen in Table 6.3. No 
differences were found in scoring of the 10 samples of tissue from tumors that 
metastasized to lymph nodes (data not shown). As stated previously, all tumor tissues 
were positive for ERα36 and 82.5% of the samples exhibited ERα36 positivity in more 
than 50% of the cells. The majority of samples exhibited ERα36 predominantly non-
nuclearly (80%), and 85% of the samples exhibited high levels of ERα36. VEGF scoring 
was more evenly distributed across all scores for VEGF number, with the exception of a 
single sample exhibiting a VEGF number score of 3, indicating more than 50% of the 
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cells in the sample were positive for VEGF. VEGF intensity scoring was somewhat even 
with 57.5% of subjects scored with low VEGF intensity and 42.5% of subjects scored 
with high VEGF intensity. 
 
 




Included in the TMA were 9 controls from matched adjacent normal tissue of 
which scoring characteristics are seen in Table 6.4. Fisher’s exact test determined no 
association of tumor status, comparing the 9 tumor samples to their matched non-tumor 
controls, with ERα36 number, ERα36 location, ERα36 intensity, VEGF number, or VEGF 









Table 6.5 shows the results of Fisher’s exact test comparing ERα36 number to 
patient variables, Table 6.6 shows results for comparison of ERα36 location with patient 
variables, and Table 6.7 shows results for comparison of ERα36 intensity and patient 
variables. In this study, neither ERα36 number nor ERα36 location in all subjects 
surveyed was significantly associated with any variable presented. However, ERα36 
intensity was found to be directly associated with VEGF intensity, as well as age. After 
performing the same analysis in only ER-negative subjects (Tables A6.1, A6.2, and 
A6.3), no variables were determined to be significantly associated with ERα36 number, 
location, or intensity. However, a Fisher’s exact p-value of 0.0691 approached 
significance when analyzing the association of ERα36 number and p53 status in ER-
negative patients (Table 6.8). The same analyses were performed in a subset of TNBC 
subjects (Tables A6.4, A6.5, and A6.6). In TNBC samples, the association of ERα36 
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Table 6.7: ERα36 intensity in all patients 
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Multivariate analysis confirmed the null hypothesis in all patients in logistic 
regression models separately for ERα36 number, ERα36 location, and ERα36 intensity. 
No variables were found to significantly predict outcome, whether outcome was number, 
location, or intensity, nor was any variable found to significantly predict outcome when 
patients were stratified based on ER status or if they were TNBC subjects. 
Figure 6.2 is an example of a typical Kaplan-Meier curve showing differences in 
mortality from subjects of the entire cohort with HER2 negative vs. HER2 positive status, 
which was found to be a significant predictor of 5-year survival in this patient cohort. 
Survival analysis using the PROC LIFETEST procedure in SAS did not reveal any 
predictive value of ERα36 where 5-year mortality was concerned; however, we do see 
that HER2 status (p=0.0147), stage (p=0.0058), and lymph node status (p=0.0382, 
0.0014, and 0.0023 for N0 vs. N1-3, N0-1 vs. N2-3, and N0-2 vs. N3, respectively), 
predicted mortality in this group of patients as shown in Table 6.8. Survival analysis in 
ER-negative (Table A6.7) and TNBC (Table A6.8) subjects revealed that only node 





Figure 6.2: Kaplan-Meier Curves for all patients. 




Table 6.8: Survival in Breast TMA patients.  
Log-rank p-values in all patients. 
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Patients with high ERα36 number (score=3), which is the group of patients in 
which greater than 50% of the cells in their tumor samples were positive for ERα36, 
exhibited a correlation with mortality. Log-rank p-values for all variables can be seen in 
Table 6.9. After stratifying this group based on their ERα36 number, the log-rank test 
showed that PR status (p=0.0477), VEGF intensity (p=0.0155), stage (0.0139), tumor 
size (p=0.0092) and node status greater than 1 (p=0071) affected survival. 
 
 
Table 6.9: Survival in subjects with high ERα36 number 
Log-rank p-values in patients with high ERα36 number (score=3), which corresponds to 




A similar relationship was observed when analyzing survival of patients with high 
ERα36 intensity (score=1), which is the group of patients with qualitatively high levels of 
ERα36 present in positive cells. Log-rank p-values for all variables can be seen in Table 
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6.10. After stratifying this group based on their ERα36 intensity, the log-rank test showed 
that HER2 status (p=0.0162), stage (p=0.0386), node status greater than 1 (p=0.0131), 
and node status greater than 2 (p=0.0029) affected survival (Table 6.10). 
 
 
Table 6.10: Survival in subjects with high ERα36 intensity 




We finally performed survival analysis on only patients with predominantly 
cytosolic ERα36 location (score=1), which is the group of patients with predominantly 
cytosolic and membrane presence of ERα36 in cells rather than predominant presence 
in the nucleus. Log-rank p-values for all variables can be seen in Table 6.11. After 
stratifying this group based on their ERα36 location, the Log-rank test showed that 
HER2 status (p=0.0208), stage (p=0.0015), tumor size (p=0.0292), node status greater 
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than 0 (p=0.0499), node status greater than 1 (p=0.0006), and node status greater than 
2 (p=0.0038) could predict survival. 
 
 
Table 6.11. Survival in subjects with cytosolic ERα36 location 





 In this study, we were able to independently identify several variables that were 
associated with ERα36 in a 40-subject cohort of breast cancer collected on a single slide 
in a TMA. ERα36 has been shown to mediate non-nuclear responses of estrogen in vitro 
leading to more aggressive cancer phenotype such as enhanced cell proliferation, anti-
apoptosis, and production of factors that promote angiogenesis and metastasis (54, 55). 
VEGF has been shown to be elevated in tumor tissue undergoing vascularization and is 
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associated with increased risk of metastasis (176-179). We therefore performed 
immunohistochemistry for ERα36 and VEGF in all samples in order to determine if 
ERα36 was associated with any physiologically relevant variable such as patient age, 
tumor size, metastasis, tumor stage, or VEGF presence. 
As this study only provides a snapshot of ERα36 presence in these subjects and 
not an idea of ERα36 functionality, we could not determine the actual functional role of 
ERα36 in these patients. However, the direct association of ERα36 and age, as well as 
the association of ERα36 and VEGF, provides intriguing insight into the possible role of 
ERα36 in this cohort of breast cancer patients. In addition, in vitro data suggests a 
tumorigenic role of ERα36 in a variety of cancers (59, 108, 180-182). The positive 
association of ERα36 intensity and VEGF intensity suggests that breast cancer tissue 
with higher levels of ERα36 at the cellular level, may lead to enhanced vascularization. 
Enhanced tumor vascularization would understandably aid in tumor growth and spread 
and provide a path by which cells from the primary tumor can enter the circulation either 
via the circulatory system or the lymphatic system and travel to distant sites (162, 164, 
183). Qualitatively, it appeared that ERα36 exhibited punctate expression in several 
samples that contained blood vessels and VEGF levels in these blood vessels was 
highly evident. We could not determine if these blood vessels were immature or mature 
blood vessels; however, it was notable to have seen this qualitative correlation of 
expression between ERα36 and VEGF. 
Interestingly, in this limited cohort, we did see an association between age and 
ERα36 intensity, suggesting that in older patients, ERα36 levels are higher. Although 
menopausal status of the subjects in this cohort was not obtained, we made the 
assumption that the average woman over the age of 50 is post-menopausal, whereas 
women under the age of 50 are generally pre-menopausal (173). This may not be 
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completely accurate, but as an educated assumption, if this were true for this cohort, it 
may give an idea as to the relation of ERα36 presence in breast cancer tissue in these 
patients and menopausal status. As circulating estrogen levels decline following 
menopause, breast tissue can actually maintain estrogen levels, indicating the functional 
presence of estrogen in the breast after menopause. Not only are estrogen levels 
maintained, but also in many cases, estrogen levels can actually be elevated in breast 
tumor tissue, and this can be attributed to local production of estrogen through multiple 
mechanisms including the conversion of pre-estrogens such as androstenedione and 
testosterone via the enzyme aromatase (184, 185). 
Although univariate analysis only showed an association of ERα36 with age and 
VEGF intensity, we were able to perform survival analysis and assess the individual 
prognostic value of all variables and 5-year survival. HER2 status, stage, and lymph 
node metastasis were associated with decreased mortality in the entire cohort, indicating 
that these variables could possibly predict survival. In ER-negative patients and TNBC 
patients, node status also affected survival, which was not surprising as lymph node 
metastasis is a logical precursor to distant metastasis, which makes cancer more difficult 
to treat leading to poor prognosis. 
Survival analysis of patients in which their tumors showed greater than 50% of 
cells positive for ERα36 showed the same variables predictive of survival than the entire 
cohort, as did the subset of patients with high ERα36 intensity or predominantly non-
nuclear localization of ERα36. In fact, in the subset of patients with high amounts of 
ERα36 (ERα36 number=3), PR status also showed significant predictive value for 
survival. The entire undivided cohort showed a p-value for PR prediction for survival of 
0.0657 and although this is not statistically significant at a significance level of 0.05, it is 
approaching significance. When we performed the analysis on the patient subset that 
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expressed high amounts of ERα36, we did see a significant predictive value of PR 
status, suggesting some unknown association of ERα36 and PR where survival is 
concerned. Interestingly, VEGF intensity and node status were associated with 
decreased survival in this subset of patients, and the fact that ERα36 and VEGF were 
directly associated by univariate analysis, and ERα36 promotes VEGF expression in 
breast cancer cells, the poor outcome may be explained by the ability of ERα36 to 
promote tumor vascularization, leading to metastasis, and thus, poor survival. 
Limitations of this study include missing data such as treatment, race, status of 
genetic mutations such as BRCA1/2, non-cancerous abnormal breast conditions, weight, 
circulating E2 levels, history of alcohol use, history of pregnancy, number of children, 
history of birth control use, family history and the low sample size. Most if not all of these 
limitations could be alleviated by performing this study on a prospective cohort in which 
all of these factors could be included with patient information with all patients enrolled in 
the study. A retrospective cohort from whom more patient information is obtainable 
would also provide a more accurate idea of some of the associations of these variables 
with outcome. Unfortunately, due to the constraints of this study as far as sample size 
and subject information is concerned, the inability to find significant associations 
between variables and outcome does not provide a generalizable idea of whether these 
variables do in fact play a role in outcome. However, the data presented in this study, 
especially in showing significant association of several variables and ERα36, as well as 
many of these variables and effects on survival in this cohort, suggest the robustness of 
these variables’ predictive values. If these variables could be found significantly 
predictive of the outcomes examined here considering the low sample size, they will 
most likely prove to be significant in a study with a larger sample size. 
 128 
This study, as limited as it may be due to small sample size, is one of the first 
studies showing the association of ERα36 and VEGF in human breast cancer patients 
using a tissue microarray that allows for consistent immunohistochemical evaluation 
among all samples in the TMA. The results of this preliminary study show independent 
association of ERα36 and VEGF, as well as ERα36 and age. Furthermore, it shows that 
survival in patients with high amounts of ERα36 can be associated with several variables 
including PR status, HER2 status, stage, tumor size, and node status. Although ERα36 
itself was not able to show a predictive value for survival in this patient cohort, the 
significant predictive value of the other variables in patients with high levels of ERα36 
suggest that ERα36 may be an important factor with which to perform a further, more 
extensive analysis. A larger cohort may give a clearer idea of the role of ERα36 on 
patient outcome. The fact that several of the variables analyzed in this study did in fact 
show a significant association with the outcomes measured suggests that these factors 
in particular may be very robust in predicting outcome. 
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Due to the heterogeneity of causes and characteristics of cancer, the idea of 
finding a single, defined cure is impractical. However, new discoveries and greater 
insight into the mechanisms of cancer development and progression can provide novel 
methods for treatment. In some cases, treatments can be so effective, they can extend 
life expectancy and patient quality of life in such a way as to essentially cure the patient 
of the physical manifestations of cancer. Because every patient presents a unique case, 
discovery of novel drug targets allows for several routes of treatment in single subjects. 
Instead of just simple physical removal of cancerous tumors by surgery or prevention of 
tumor growth by radiotherapy, several adjunct chemotherapeutic treatments have been 
developed that allow for more personalized treatment, depending on the specific 
characteristics of the patient and the tumor. Standard chemotherapy, which aims to fight 
cancer through cytotoxicity, does not differentiate among cells and not only kills cancer 
cells, but may also affect normal cells, leading to adverse side effects. Especially due to 
these generalized effects of standard chemotherapy in patients, the need for more 
tailored and effective treatments with reduced side effects is more prevalent than ever. 
Personalized medicine is rapidly become the ideal route of treatment for several 
diseases. In cancer, personalization of treatment is especially beneficial due to the 
heterogeneity of cancer. Several drugs have either recently been approved or are in the 
process of achieving approval by the FDA for use as adjuvant treatments for cancer. 
One of the most common approaches to personalized medicine in cancer treatment is 
immunotherapy or targeting of biomarkers that are overexpressed in cancer tissue. The 
discovery of novel biological targets that are more prevalent in cancer tissue than normal 
tissue provides a more practical route of treatment than standard chemotherapeutics, 
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which tend to not differentiate between normal and cancerous cells. Several companies 
currently produce drugs that exploit the overexpression of biological targets in cancer 
tissue compared to normal tissue. Trastuzumab, a monoclonal antibody that targets 
HER2 receptor in breast cancer, is especially effective in treating breast cancer tumors 
that highly overexpress HER2. HER2/neu receptors, which can be found in the plasma 
membrane of some breast cancer cells, promote cell proliferation, and trastuzumab 
binding to HER2/neu receptors causes cell cycle arrest and decreased proliferation of 
cancer cells overexpressing the receptor. This drug can only be beneficial to a subset of 
subjects that have HER2/neu overexpression in the cancerous tissue, and therefore, not 
all patients can benefit from its use. Moreover, like most chemotherapeutics, 
trastuzumab is meant for use as an adjunct treatment along with more conventional 
methods such as surgery or radiotherapy. However, trastuzumab provides an excellent 
example of a novel chemotherapeutic that can lead to beneficial, personalized treatment 
in a select subset of breast cancer patients. 
The identification and investigation of the role of novel biological targets in cancer 
progression is necessary to predict and evaluate the possibility of drugs that may 
specifically bind and alter the function of these targets. This thesis identified ERα36 as a 
potential target in the treatment of a select group of breast cancer subjects exhibiting 
high expression of the membrane receptor. The fact that this receptor functions 
specifically from the membrane in ER-negative and TNBC patients creates hopeful 
optimism that targeting this receptor at the membrane with a drug that cannot enter the 
cells, would provide an alternative and effective method of treatment in patients who are 
difficult to treat with conventional methods. 
In this thesis, ERα36 was shown to mediate the rapid membrane-delimited 
effects of E2 in triple negative breast cancer cells as well as other cells. The activation of 
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this pathway occurred in ER-positive breast cancer cells (MCF7), TNBC cells (HCC38), 
and laryngeal cancer cells (Hep2), as well as an embryonic kidney cell line that was 
transfected to overexpress ERα36 (Hek293). Several other cell lines were screened for 
the presence of ERα36, and in all cells, ERα36 expression was apparent, however, the 
extent of expression to the level of functionality was not evaluated in all of these cell 
lines. This work proposes a mechanism, based on experimental evidence, of the rapid 
effects of E2 through membrane-associated ERα36 on cell proliferation and anti-
apoptosis. This mechanism was found to include divergent pathways from the plasma 
membrane that reconverge downstream to affect cancer cell survivability. The rapid 
activation of PKC by E2 through membrane-associated ERα36 was found to require 
activation of G-proteins that lead to activation of PLC, DAG, IP3, calcium signaling, and 
PKC. Activation of PKC leads to downstream activation of MAPkinase, which can effect 
proliferation, as well as gene transcription via MAP kinase phosphorylation of an array of 
transcription factors. At the same time, ERα36 can mediate an effect of E2 on PLD at the 
membrane leading to activation of LPA signaling and PI3K, which in turn leads to 
attenuation of the caspase cascade that promotes apoptosis, and therefore, E2’s effect 
on this pathway can promote anti-apoptosis, especially in the presence of 
chemotherapeutics that aim to induce apoptosis. In this study, we found that E2 reduced 
the effect of taxol, a common chemotherapeutic drug that causes cancer cell death, and 
that this reduction occurred through the specific pathway mediated by ERα36. 
Through examination of the presence of ERα36 in a breast cancer tissue 
microarray and a laryngeal cancer tissue microarray, ERα36 was found to be associated 
with specific factors of poor outcome such as tumor vascularization and metastasis. It 
was also found that in breast tissues with high levels of ERα36, patient survival was 
reduced when previously identified predictors of survival were examined, suggesting that 
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ERα36 may have a role in the effect of these predictors on outcome. Although in many 
of our analyses, ERα36 was not directly correlated to outcome, the results presented 
suggest further examination of the role of ERα36 in breast cancer and laryngeal cancer 
in a larger cohort of subjects with more complete information, especially including patient 
treatment, is necessary. The results of a larger study would more definitely describe a 
role of ERα36 in breast cancer and would support the diagnostic value of ERα36 or the 
importance of developing drugs that may target ERα36. 
We have currently commenced in vivo studies modeling breast tumor growth and 
breast tumor osteolysis in mice. The goal of these studies is to first establish models of 
tumor growth and osteolysis in order to determine the role of ERα36 in vivo. In our 
current models, we have included treatment groups with E2 and tamoxifen to evaluate 
the importance of E2 in the growth and osteolytic effects of the tumors. The next step is 
to create tumors with reduced ERα36 expression by mRNA knockdown in the cancer 
cells prior to injection into the mice. We hypothesize that ERα36-silenced tumors exhibit 
reduced growth and reduced osteolysis in vivo compared to wildtype tumors. Further 
studies include production of monoclonal antibodies against ERα36, which can then be 
used in several studies to first evaluate the effectiveness of the antibodies, followed by 
preclinical studies to determine if use of monoclonal antibodies in vivo can reduce tumor 
progression. If these preclinical studies prove efficacy in the use of monoclonal 
antibodies to target ERα36 in vivo, we would suggest clinical trials of the monoclonal 
antibodies in breast cancer patients exhibiting tumor overexpression of ERα36. Although 
these future approaches provide optimism in a novel approach to personalized breast 
cancer therapy by targeting ERα36, it would be tragic to not pursue these studies, which 
would give a definitive conclusion into the role of ERα36 in breast cancer and the 











Figure A3.1: Membrane estrogen signaling increases expression of membrane 
syndecan-4, but not through ERα36. 
qRT-PCR analysis indicates that E2 signaling in HCC38 cells increases expression of 
syndecan-4 (A), and E2-BSA has a similar effect (B). * p<0.05 compared to control + 
vehicle (0M E2-BSA), # p<0.05 compared to control + 10-7M E2-BSA. 
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APPENDIX II: Chapter 4 Supplemental Figures 
 
 
Figure A4.1: ERα36 and the Anti-apoptotic Effect of E2-BSA 
Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2-BSA, while ERα36 
antibodies block this effect. Data is represented by the mean of 6 individual samples and 
error bars represent standard error of the mean. * represents p<0.05 compared to the 
untreated control group while # represents p<0.05 compared to 20µM taxol and $ 




Figure A4.2: ERα36 Silencing and Overexpression 
(A) Using anti-ERα36 antibodies, western blots were performed on whole cell lysates 
from HCC38 cells transiently transfected with a non-target control vector (NT), wildtype 
HCC38 cells (WT), and HCC38 cells transiently transfected with ERα36 shRNA vector 
(shERα36). Densitometry analysis showed greater than 70% knockdown of ERα36 
protein levels in the shERα36 cells compared to wildtype controls. All samples were 
normalized to GAPDH. (B) Using ant-ERα antibodies that also recognize ERα36, 
western blots were performed on whole cell lysates from wildtype HEK293 cells (293wt), 
and HEK293 transiently transfected to overexpress wildtype ERα36 cDNA (293ovrx36) 




Figure A4.3: Phospholipases and the Anti-apoptotic Effect of E2-BSA 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2, while U73122  and 
(B) D609 block taxol’s effect. Data is represented by the mean of 6 individual samples 
and error bars represent standard error of the mean. * represents p<0.05 compared to 
the untreated control group while # represents p<0.05 compared to 20µM taxol and $ 




Figure A4.4: LPA Signaling, PI3K and the Anti-apoptotic Effect of E2-BSA 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2-BSA, while the 
LPAR1/3 antagonist, VPC32183S, does not allow E2-BSA to block the effect of taxol. 
Data is represented by the mean of 6 individual samples and error bars represent 
standard error of the mean. * represents p<0.05 compared to the untreated control 
group while # represents p<0.05 compared to 20µM taxol and $ represents p<0.05 
compared to inhibitor alone. (B) Taxol-induced (20µM) caspase-3 activity is reduced by 
10-8M E2-BSA, while the LY294002 does not allow E2-BSA to block the effect of taxol. 
Data is represented by the mean of 6 individual samples and error bars represent 
standard error of the mean. * represents p<0.05 compared to the untreated control 
group while # represents p<0.05 compared to 20µM taxol and $ represents p<0.05 




Figure A4.5: Role of Ca++ and G-protein Signaling in Apoptotic Signaling of E2-BSA 
(A) Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2-BSA , while 
thapsigargin enhances caspase-3 activity alone and this is also reduced by E2-BSA . (B) 
Taxol-induced (20µM) caspase-3 activity is reduced by 10-8M E2-BSA , while pertussis 
toxin and cholera toxin both enhance caspase-3 activity alone. The effect of CTX is 
reduced by E2-BSA . Data is represented by the mean of 6 individual samples and error 
bars represent standard error of the mean. * represents p<0.05 compared to the 
untreated control group while # represents p<0.05 compared to 20µM taxol and $ 




Figure A4.6: Palmitoylation and the Anti-apoptotic Effect of E2-BSA 
(A) Western blot of plasma membrane fractions of HCC38 cells treated with 10-8M E2 for 
9 minutes, pre-treated with 0.5mM HMA, 30µM Tm, or 10µM 2-BP for 2 hours indicates 
that ERα36 membrane-association occurs rapidly and is blocked by Tm and 2-BP. (B,C) 
Tm and 2-BP prevent the effect of 10-8M E2 on (B) Taxol-induced (20µM) caspase-3 
activity is reduced by 10-8M E2-BSA, while Tm (30µM) blocked this effect. Data is 
represented by the mean of 6 individual samples and error bars represent standard error 
of the mean. * represents p<0.05 compared to the untreated control group while # 
represents p<0.05 compared to 20µM taxol and $ represents p<0.05 compared to 
inhibitor alone. @ represents p<0.05 compared to taxol and 2-BP alone. 
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APPENDIX III: Chapter 5 Supplemental Figures 
 
Figure A5.1: mRNA levels normalized to RPS18 
10-8M E2 increased mRNA levels of pro-angiogenic factors VEGF(A) and FGF2(B), and 
the metastatic factors CXCR4(C) and Snail1(D), while antibodies to ERα36 blocked this 
effect. The effects on Snail1 were accompanied by a corresponding decrease in E-
Cadherin mRNA levels that was also inhibited by ERα36 antibodies(E). All values were 
normalized to RPS18 mRNA levels. *p<0.05 vs. corresponding control; #p<0.05 vs. E2 
only. 
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Table A6.3: ERα36 intensity in ER-negative subjects 
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Table A6.7. Survival in subjects with ER-negative 
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